Pfizer Inc.

(NYSE:PFE) > Financials > Key Stats

In Millions of the trading currency, except per share items. Currency: Trading Currency Conversion: Today's Spot Rate
Order: Latest on Right Units: S&P Capital IQ (Default)
Decimals: Capital IQ (Default) Dilution: Basic

Key Financials¹
For the Fiscal Period Ending
12 months 12 months 12 months 12 months 12 months 12 months†
Currency USD USD USD USD USD USD

Total Revenue 52,824.0 52,546.0 40,825.0 41,172.0 41,908.0 62,028.01

Growth Over Prior Year 8.1% (0.5%) (22.3%) 0.8% 1.8% 48.01%

Gross Profit 40,906.0 41,720.0 31,953.0 33,129.0 33,334.0 -

Margin % 77.4% 79.4% 78.3% 80.5% 79.5% 67.55%

EBITDA 19,648.0 20,889.0 13,467.0 14,134.0 14,887.0 24,503.69

Margin % 37.2% 39.8% 33.0% 34.3% 35.5% 39.50%

EBIT 14,098.0 14,711.0 7,355.0 8,379.0 10,129.0 19,587.64

Margin % 26.7% 28.0% 18.0% 20.4% 24.2% 31.58%

Earnings from Cont. Ops. 7,230.0 21,353.0 3,861.0 10,867.0 7,021.0 -

Margin % 13.7% 40.6% 9.5% 26.4% 16.8% -

Net Income 7,215.0 21,308.0 11,153.0 16,273.0 9,616.0 19,117.16

Margin % 13.7% 40.6% 27.3% 39.5% 22.9% 30.82%

Diluted EPS Excl. Extra Items³ 1.17 3.52 0.64 1.91 1.24 3.34
Growth Over Prior Year 5.3% 200.6% (81.8%) 198.4% (35.1%) 50.64%

¹All results are taken from the most recently filed statement for each period. When there has been more than one, earlier filings can be viewed on the individual statement pages.
³All forward period figures are consensus mean estimates provided by the brokers and may not be on a comparable basis as financials.
†Growth rates for forward periods are calculated against prior period estimates or actual pro forma results as disclosed on the Estimates Consensus page.

Current Capitalization (Millions of USD)

Currency USD
Share Price $34.94
Shares Out. 5,578.2

Market Capitalization 194,901.1

- Cash & Short Term Investments 12,239.0
+ Total Debt 41,271.0
+ Pref. Equity -
+ Total Minority Interest 235.0
= Total Enterprise Value (TEV) 224,168.1

Book Value of Common Equity 63,238.0

+ Pref. Equity -
+ Total Minority Interest 235.0
+ Total Debt 41,271.0
= Total Capital 104,744.0

**For companies that have multiple share classes that publicly trade,
we are incorporating the different prices to calculate our company level

Total Liability includes Total Debt, Minority Interest and Pref. Equity.
Net Liability includes Total Liability, net of Cash and Short Term Investments.
TEV includes Market Cap and Net Liability.
Total Capital includes Common Equity and Total Liability.

Valuation Multiples based on Current Capitalization

For the Fiscal Period Ending
12 months 12 months 12 months 12 months 12 months
TEV/Total Revenue 5.4x 5.3x 3.61x 4.20x 4.32x

TEV/EBITDA 15.1x 14.0x 9.15x 9.77x 9.79x

TEV/EBIT 26.7x 21.5x 11.44x 12.08x 11.75x

P/Diluted EPS Before Extra 18.3x 28.2x 10.45x 11.38x 10.99x

P/BV 3.1x 3.1x 2.61x 2.41x 2.51x

Price/Tang BV NM NM - - -
12 months 12 months
USD USD

53,325.53 51,884.0
(14.03%) (2.70%)

- -
75.99% 79.16%

22,951.86 22,896.47
43.04% 44.13%

18,554.95 19,071.37
34.80% 36.76%

- -
- -

17,197.39 17,772.35
32.25% 34.25%

3.07 3.18
(8.22%) 3.57%
Pfizer Inc. (NYSE:PFE) > Financials > Income Statement

In Millions of the reported currency, except per share items. Template: Standard Restatement: Latest Filings
Period Type: Annual Order: Latest on Right
Currency: Reported Currency Conversion: Today's Spot Rate
Units: S&P Capital IQ (Defaul Decimals: Capital IQ (Default)
Source: Capital IQ & Proprietar

Income Statement
For the Fiscal Period Ending
12 months Reclassified Reclassified Reclassified Reclassified 12 months
Currency USD USD USD USD USD USD

Revenue 48,851.0 52,824.0 52,546.0 40,825.0 41,172.0 41,908.0

Other Revenue - - - - - -
Total Revenue 48,851.0 52,824.0 52,546.0 40,825.0 41,172.0 41,908.0

Cost Of Goods Sold 9,361.0 11,918.0 10,826.0 8,872.0 8,043.0 8,574.0

Gross Profit 39,490.0 40,906.0 41,720.0 31,953.0 33,129.0 33,334.0

Selling General & Admin Exp. 14,325.0 14,894.0 14,606.0 12,149.0 12,557.0 10,890.0
R & D Exp. 7,646.0 7,858.0 7,645.0 7,713.0 7,731.0 8,879.0
Depreciation & Amort. - - - - - -
Amort. of Goodwill and Intangibles 3,728.0 4,056.0 4,758.0 4,736.0 4,462.0 3,436.0
Other Operating Expense/(Income) - - - - - -

Other Operating Exp., Total 25,699.0 26,808.0 27,009.0 24,598.0 24,750.0 23,205.0

Operating Income 13,791.0 14,098.0 14,711.0 7,355.0 8,379.0 10,129.0

Interest Expense (1,199.0) (1,186.0) (1,270.0) (1,316.0) (1,573.0) (1,449.0)

Interest and Invest. Income 471.0 470.0 657.0 586.0 445.0 351.0
Net Interest Exp. (728.0) (716.0) (613.0) (730.0) (1,128.0) (1,098.0)

Income/(Loss) from Affiliates 45.0 - - - 17.0 298.0

Currency Exchange Gains (Loss) 937.0 (64.0) (120.0) - - -
Other Non-Operating Inc. (Exp.) 996.0 1,353.0 712.0 1,009.0 1,376.0 1,619.0
EBT Excl. Unusual Items 15,041.0 14,671.0 14,690.0 7,634.0 8,644.0 10,948.0
Restructuring Charges (534.0) (2,365.0) (701.0) (1,332.0) (1,093.0) (859.0)
Merger & Related Restruct. Charges (1,227.0) (219.0) (30.0) (19.0) (2.0) (528.0)
Impairment of Goodwill - - - - - -
Gain (Loss) On Sale Of Invest. (1,256.0) (385.0) 235.0 445.0 8,540.0 546.0
Gain (Loss) On Sale Of Assets 88.0 101.0 151.0 71.0 32.0 (237.0)
Asset Writedown (621.0) (945.0) (352.0) (3,115.0) (2,843.0) (1,691.0)
Legal Settlements (975.0) (510.0) (240.0) (84.0) (292.0) (28.0)
Other Unusual Items (1,551.0) (1,995.0) (1,449.0) (5.0) (1,501.0) (653.0)
EBT Incl. Unusual Items 8,965.0 8,353.0 12,304.0 3,595.0 11,485.0 7,498.0

Income Tax Expense 1,990.0 1,123.0 (9,049.0) (266.0) 618.0 477.0

Earnings from Cont. Ops. 6,975.0 7,230.0 21,353.0 3,861.0 10,867.0 7,021.0

Earnings of Discontinued Ops. 11.0 16.0 2.0 7,328.0 5,435.0 2,631.0

Extraord. Item & Account. Change - - - - - -
Net Income to Company 6,986.0 7,246.0 21,355.0 11,189.0 16,302.0 9,652.0

Minority Int. in Earnings (26.0) (31.0) (47.0) (36.0) (29.0) (36.0)

Net Income 6,960.0 7,215.0 21,308.0 11,153.0 16,273.0 9,616.0

Pref. Dividends and Other Adj. 1.0 1.0 1.0 1.0 1.0 -

NI to Common Incl Extra Items 6,959.0 7,214.0 21,307.0 11,152.0 16,272.0 9,616.0
NI to Common Excl. Extra Items 6,948.0 7,198.0 21,305.0 3,824.0 10,837.0 6,985.0

Per Share Items

Basic EPS $1.13 $1.18 $3.57 $1.9 $2.92 $1.73
Basic EPS Excl. Extra Items 1.13 1.18 3.57 0.65 1.95 1.26
Weighted Avg. Basic Shares Out. 6,176.0 6,089.0 5,970.0 5,872.0 5,569.0 5,555.0

Diluted EPS $1.11 $1.17 $3.52 $1.87 $2.87 $1.71

Diluted EPS Excl. Extra Items 1.11 1.17 3.52 0.64 1.91 1.24
Weighted Avg. Diluted Shares Out. 6,257.0 6,159.0 6,058.0 5,977.0 5,675.0 5,632.0

Normalized Basic EPS $1.52 $1.5 $1.53 $0.81 $0.96 $1.23

Normalized Diluted EPS 1.5 1.48 1.51 0.79 0.95 1.21

Dividends per Share $1.12 $1.2 $1.28 $1.36 $1.44 $1.52

Payout Ratio % 99.7% 101.4% 35.9% 71.5% 49.4% 87.8%

Shares per Depository Receipt 0.25 0.25 0.25 0.25 0.25 0.25

Supplemental Items
EBITDA 18,826.0 19,648.0 20,889.0 13,467.0 14,134.0 14,887.0
EBITA 17,519.0 18,154.0 19,469.0 12,091.0 12,841.0 13,565.0
EBIT 13,791.0 14,098.0 14,711.0 7,355.0 8,379.0 10,129.0
EBITDAR 19,069.0 19,940.0 21,203.0 13,768.0 14,838.0 15,660.0
Effective Tax Rate % 22.2% 13.4% NM NM 5.4% 6.4%
Current Domestic Taxes 59.0 290.0 14,447.0 (2,696.0) (2,208.0) 429.0
Current Foreign Taxes 1,951.0 1,532.0 2,709.0 2,195.0 2,418.0 1,517.0
Total Current Taxes 2,010.0 1,822.0 17,156.0 (501.0) 210.0 1,946.0
Deferred Domestic Taxes 264.0 (525.0) (26,163.0) 813.0 1,272.0 (1,176.0)
Deferred Foreign Taxes (284.0) (175.0) (42.0) (579.0) (863.0) (292.0)
Total Deferred Taxes (20.0) (700.0) (26,205.0) 234.0 409.0 (1,468.0)

Normalized Net Income 9,374.6 9,138.4 9,134.3 4,735.3 5,373.5 6,806.5

Interest Capitalized 32.0 61.0 72.0 73.0 88.0 96.0
Non-Cash Pension Expense 708.0 256.0 231.0 (138.0) 206.0 (76.0)
Filing Date Feb-22-2018 Feb-28-2019 Feb-27-2020 Feb-25-2021 Feb-25-2021 Feb-25-2021
Restatement Type NC RC RC RD RD O
Calculation Type REP REP REP REP REP REP

Supplemental Operating Expense Items

Advertising Exp. 3,100.0 3,200.0 3,100.0 2,700.0 2,400.0 1,800.0
Selling and Marketing Exp. 3,100.0 3,200.0 3,100.0 2,700.0 2,400.0 1,800.0
R&D Exp. 7,690.0 7,892.0 7,683.0 7,760.0 8,394.0 9,405.0
Net Rental Exp. 243.0 292.0 314.0 301.0 704.0 773.0
Imputed Oper. Lease Interest Exp. 63.2 71.7 78.5 78.0 195.8 201.7
Imputed Oper. Lease Depreciation 179.8 220.3 235.5 223.0 508.2 571.3

Stock-Based Comp., Unallocated 677.0 700.0 851.0 941.0 708.0 776.0

Stock-Based Comp., Total 677.0 700.0 851.0 941.0 708.0 776.0

Note: For multiple class companies, per share items are primary class equivalent, and for foreign companies listed as primary ADRs, per share items are ADR-equivalent.
Pfizer Inc. (NYSE:PFE) > Financials > Balance Sheet

In Millions of the reported currency, except per share items. Template: Standard Restatement: Latest Filings
Period Type: Annual Order: Latest on Right
Currency: Reported Currency Conversion: Today's Spot Rate
Units: S&P Capital IQ (Defaul Decimals: Capital IQ (Default)
Source: Capital IQ & Proprietar

Balance Sheet
Balance Sheet as of:
Restated Dec-31-2016 Dec-31-2017 Dec-31-2018 Restated Dec-31-2020
Currency USD USD USD USD USD USD
ASSETS
Cash And Equivalents 3,641.0 2,595.0 1,342.0 1,139.0 1,121.0 1,784.0
Short Term Investments 19,649.0 15,255.0 18,650.0 17,694.0 8,525.0 10,437.0
Trading Asset Securities 2.0 26.0 104.0 97.0 53.0 18.0
Total Cash & ST Investments 23,292.0 17,876.0 20,096.0 18,930.0 9,699.0 12,239.0

Accounts Receivable 8,176.0 8,225.0 8,221.0 8,025.0 6,772.0 7,930.0

Other Receivables 2,662.0 3,041.0 3,050.0 3,374.0 2,736.0 3,264.0
Total Receivables 10,838.0 11,266.0 11,271.0 11,399.0 9,508.0 11,194.0

Inventory 7,513.0 6,783.0 7,578.0 7,508.0 7,068.0 8,046.0

Restricted Cash - - 14.0 - - -
Other Current Assets 2,161.0 3,024.0 2,183.0 12,089.0 6,528.0 3,588.0
Total Current Assets 43,804.0 38,949.0 41,142.0 49,926.0 32,803.0 35,067.0

Gross Property, Plant & Equipment 27,268.0 28,125.0 30,037.0 29,976.0 29,248.0 30,105.0
Accumulated Depreciation (13,502.0) (14,807.0) (16,172.0) (16,591.0) (14,990.0) (14,812.0)
Net Property, Plant & Equipment 13,766.0 13,318.0 13,865.0 13,385.0 14,258.0 15,293.0

Long-term Investments 16,834.0 7,715.0 7,492.0 3,102.0 20,413.0 20,379.0

Goodwill 48,242.0 54,449.0 55,952.0 53,411.0 48,202.0 49,577.0
Other Intangibles 40,356.0 52,648.0 48,741.0 35,211.0 33,936.0 28,471.0
Deferred Tax Assets, LT 732.0 654.0 700.0 800.0 700.0 900.0
Other Long-Term Assets 3,647.0 3,882.0 3,905.0 3,587.0 17,282.0 4,542.0
Total Assets 167,381.0 171,615.0 171,797.0 159,422.0 167,594.0 154,229.0
LIABILITIES
Accounts Payable 3,620.0 4,536.0 4,656.0 4,674.0 3,887.0 4,309.0
Accrued Exp. 2,359.0 5,257.0 5,382.0 6,136.0 5,281.0 6,511.0
Short-term Borrowings 6,440.0 6,463.0 6,407.0 4,055.0 14,733.0 701.0
Curr. Port. of LT Debt 3,724.0 4,226.0 3,547.0 4,781.0 1,462.0 2,002.0
Curr. Port. of Leases - - - - 269.0 321.0
Curr. Income Taxes Payable 418.0 437.0 477.0 1,265.0 980.0 1,049.0
Unearned Revenue, Current - - - - - 957.0
Other Current Liabilities 12,837.0 10,196.0 9,958.0 10,947.0 10,692.0 10,070.0
Total Current Liabilities 29,398.0 31,115.0 30,427.0 31,858.0 37,304.0 25,920.0

Long-Term Debt 28,874.0 31,545.0 33,715.0 33,287.0 35,955.0 37,133.0

Long-Term Leases - - - - 1,030.0 1,114.0
Pension & Other Post-Retire. Benefits 8,119.0 8,172.0 7,430.0 6,610.0 6,217.0 5,411.0
Def. Tax Liability, Non-Curr. 26,877.0 30,753.0 3,900.0 3,700.0 5,652.0 4,063.0
Other Non-Current Liabilities 9,115.0 10,190.0 24,669.0 20,209.0 17,990.0 17,115.0
Total Liabilities 102,383.0 111,775.0 100,141.0 95,664.0 104,148.0 90,756.0

Pref. Stock, Convertible 26.0 24.0 21.0 19.0 17.0 -

Total Pref. Equity 26.0 24.0 21.0 19.0 17.0 -

Common Stock 459.0 461.0 464.0 467.0 468.0 470.0

Additional Paid In Capital 81,016.0 82,685.0 84,278.0 86,253.0 87,428.0 88,674.0
Retained Earnings 71,993.0 71,774.0 85,291.0 89,554.0 97,670.0 96,770.0
Treasury Stock (79,252.0) (84,364.0) (89,425.0) (101,610.0) (110,801.0) (110,988.0)
Comprehensive Inc. and Other (9,522.0) (11,036.0) (9,321.0) (11,276.0) (11,639.0) (11,688.0)
Total Common Equity 64,694.0 59,520.0 71,287.0 63,388.0 63,126.0 63,238.0

Minority Interest 278.0 296.0 348.0 351.0 303.0 235.0

Total Equity 64,998.0 59,840.0 71,656.0 63,758.0 63,446.0 63,473.0

Total Liabilities And Equity 167,381.0 171,615.0 171,797.0 159,422.0 167,594.0 154,229.0

Supplemental Items
Total Shares Out. on Filing Date 6,184.1 5,951.9 5,952.9 5,551.8 5,547.6 5,577.6
Total Shares Out. on Balance Sheet Date 6,175.0 6,070.0 5,979.0 5,717.0 5,534.0 5,567.0
Book Value/Share $10.48 $9.81 $11.92 $11.09 $11.41 $11.36
Tangible Book Value (23,904.0) (47,577.0) (33,406.0) (25,234.0) (19,012.0) (14,810.0)
Tangible Book Value/Share ($3.87) ($7.84) ($5.59) ($4.41) ($3.44) ($2.66)
Total Debt 39,038.0 42,234.0 43,669.0 42,123.0 53,449.0 41,271.0
Net Debt 15,746.0 24,358.0 23,573.0 23,193.0 43,750.0 29,032.0
Debt Equiv. of Unfunded Proj. Benefit Obligation 5,891.0 6,449.0 5,657.0 5,107.0 5,403.0 4,402.0
Debt Equivalent Oper. Leases 1,944.0 2,336.0 2,512.0 2,408.0 5,632.0 6,184.0
Total Minority Interest 278.0 296.0 348.0 351.0 303.0 235.0
Equity Method Investments 775.0 270.0 NA 181.0 17,133.0 16,856.0
Inventory Method Avg Cost Avg Cost Avg Cost Avg Cost Avg Cost Avg Cost
Raw Materials Inventory 867.0 793.0 788.0 546.0 672.0 738.0
Work in Progress Inventory 3,932.0 3,697.0 3,907.0 4,700.0 4,131.0 4,430.0
Finished Goods Inventory 2,714.0 2,293.0 2,883.0 2,262.0 2,265.0 2,878.0
Land 588.0 530.0 540.0 500.0 495.0 444.0
Buildings 9,604.0 9,810.0 10,254.0 9,920.0 9,181.0 9,022.0
Machinery 15,285.0 15,658.0 16,563.0 16,564.0 15,489.0 15,694.0
Construction in Progress 1,791.0 2,127.0 2,680.0 2,992.0 2,794.0 3,552.0
Full Time Employees 97,900 96,500 90,200 92,400 88,300 78,500
Accum. Allowance for Doubtful Accts 384.0 609.0 584.0 541.0 493.0 508.0
Filing Date Feb-22-2018 Feb-28-2019 Feb-27-2020 Feb-25-2021 Feb-25-2021 Feb-25-2021
Restatement Type RS NC NC NC RS O
Calculation Type RUP RUP RUP RUP REP REP

Note: For multiple class companies, total share counts are primary class equivalent, and for foreign companies listed as primary ADRs, total share counts are ADR-equivalent.
Pfizer Inc. (NYSE:PFE) > Financials > Cash Flow

In Millions of the reported currency, except per share items. Template: Standard Restatement: Latest Filings
Period Type: Annual Order: Latest on Right
Currency: Reported Currency Conversion: Today's Spot Rate
Units: S&P Capital IQ (Defaul Decimals: Capital IQ (Default)
Source: Capital IQ & Proprietar

Cash Flow
For the Fiscal Period Ending
Restated Restated Restated Reclassified Reclassified 12 months
Currency USD USD USD USD USD USD

Net Income 6,960.0 7,215.0 21,308.0 11,153.0 16,273.0 9,616.0

Depreciation & Amort. 1,307.0 1,494.0 1,420.0 1,376.0 1,293.0 1,322.0
Amort. of Goodwill and Intangibles 3,728.0 4,056.0 4,758.0 4,736.0 4,462.0 3,436.0
Depreciation & Amort., Total 5,035.0 5,550.0 6,178.0 6,112.0 5,755.0 4,758.0

(Gain) Loss On Sale Of Invest. - - - - (8,233.0) (6.0)

Asset Writedown & Restructuring Costs 1,241.0 3,532.0 725.0 3,436.0 2,981.0 2,068.0
Stock-Based Compensation 669.0 691.0 840.0 923.0 688.0 756.0
Net Cash From Discontinued Ops. - - - 6,952.0 5,576.0 3,817.0
Other Operating Activities 42.0 (894.0) (13,583.0) (12,415.0) (6,499.0) (6,331.0)
Change in Acc. Receivable 21.0 (134.0) 259.0 (458.0) (1,140.0) (1,249.0)
Change In Inventories (199.0) 365.0 (357.0) (432.0) (1,080.0) (736.0)
Change in Acc. Payable 254.0 871.0 46.0 404.0 (340.0) 353.0
Change in Other Net Operating Assets 665.0 (1,004.0) 1,386.0 152.0 (1,393.0) 1,357.0
Cash from Ops. 14,688.0 16,192.0 16,802.0 15,827.0 12,588.0 14,403.0

Capital Expenditure (1,397.0) (1,823.0) (1,956.0) (1,984.0) (2,072.0) (2,252.0)

Cash Acquisitions (16,466.0) (18,368.0) (1,000.0) - (10,861.0) -
Divestitures - - - - - -
Sale (Purchase) of Intangible assets (99.0) (176.0) (261.0) (152.0) (418.0) (539.0)
Invest. in Marketable & Equity Securt. 14,638.0 12,496.0 (2,194.0) 6,434.0 9,304.0 (1,672.0)
Net (Inc.) Dec. in Loans Originated/Sold - - - - - -
Other Investing Activities 344.0 80.0 671.0 227.0 102.0 192.0
Cash from Investing (2,980.0) (7,791.0) (4,740.0) 4,525.0 (3,945.0) (4,271.0)
Short Term Debt Issued 8,274.0 7,472.0 9,886.0 3,711.0 19,006.0 12,352.0
Long-Term Debt Issued - 10,976.0 5,274.0 4,974.0 4,942.0 5,222.0
Total Debt Issued 8,274.0 18,448.0 15,160.0 8,685.0 23,948.0 17,574.0
Short Term Debt Repaid (3,965.0) (8,153.0) (9,947.0) (6,054.0) (8,378.0) (26,326.0)
Long-Term Debt Repaid (2,990.0) (7,689.0) (6,154.0) (3,566.0) (6,806.0) (4,003.0)
Total Debt Repaid (6,955.0) (15,842.0) (16,101.0) (9,620.0) (15,184.0) (30,329.0)

Issuance of Common Stock 1,263.0 1,019.0 862.0 1,259.0 394.0 425.0

Repurchase of Common Stock (6,160.0) (5,000.0) (5,000.0) (12,198.0) (8,865.0) -

Common and/or Pref. Dividends Paid (6,940.0) (7,317.0) (7,659.0) (7,978.0) (8,043.0) (8,440.0)
Total Dividends Paid (6,940.0) (7,317.0) (7,659.0) (7,978.0) (8,043.0) (8,440.0)

Special Dividend Paid - - - - - -

Other Financing Activities 109.0 (536.0) (612.0) (589.0) (735.0) 11,121.0
Cash from Financing (10,409.0) (9,228.0) (13,350.0) (20,441.0) (8,485.0) (9,649.0)

Foreign Exchange Rate Adj. (1,000.0) (215.0) 53.0 (116.0) (32.0) (8.0)
Misc. Cash Flow Adj. (1.0) 1.0 - - (1.0) -
Net Change in Cash 298.0 (1,041.0) (1,235.0) (205.0) 125.0 475.0

Supplemental Items
Cash Interest Paid 1,302.0 1,451.0 1,518.0 1,311.0 1,587.0 1,641.0
Cash Taxes Paid 2,383.0 2,521.0 2,489.0 3,655.0 3,664.0 3,153.0
Levered Free Cash Flow 13,802.0 12,952.0 13,286.6 1,290.4 13,936.8 10,500.0
Unlevered Free Cash Flow 14,551.4 13,693.3 14,080.4 2,112.9 14,919.9 11,405.6
Change in Net Working Capital (1,716.0) (631.0) (74.0) 7,401.0 (5,710.0) (2,332.0)
Net Debt Issued 1,319.0 2,606.0 (941.0) (935.0) 8,764.0 (12,755.0)
Net Cash From Discontinued Ops. - Investing - - - (60.0) (94.0) (82.0)
Net Cash From Discontinued Ops. - Financing - - - - - 11,991.0
Filing Date Feb-22-2018 Feb-28-2019 Feb-27-2020 Feb-25-2021 Feb-25-2021 Feb-25-2021
Restatement Type RS RS RS RD RD O
Calculation Type REP REP REP REP REP REP
Pfizer Inc. (NYSE:PFE) > Financials > Multiples

View: Data Frequency: Quarterly

Order: Latest on Right Decimals: Capital IQ (Default)
Dilution: Basic

Multiples Detail
In Millions of the reported currency, except per share items.

For Quarter Ending Sep-30-2019 Dec-31-2019 Mar-31-2020 Jun-30-2020 Sep-30-2020

TEV/LTM Total Revenue Average 4.61x 4.67x 4.67x 4.74x 5.12x
High 5.24x 4.96x 5.10x 5.08x 5.46x
Low 4.19x 4.24x 3.90x 4.25x 4.50x
Close 4.36x 4.94x 4.35x 4.42x 5.21x

TEV/NTM Total Revenues Average 4.84x 5.10x 4.99x 4.94x 5.17x

High 5.28x 5.42x 5.57x 5.20x 5.47x
Low 4.43x 4.63x 4.11x 4.44x 4.82x
Close 4.76x 5.39x 4.54x 4.73x 5.20x

TEV/LTM EBITDA Average 10.82x 10.86x 11.13x 11.57x 12.53x

High 12.29x 11.45x 12.12x 12.39x 13.32x
Low 9.77x 9.89x 9.29x 10.13x 11.11x
Close 10.18x 11.40x 10.35x 10.90x 12.71x

TEV/NTM EBITDA Average 11.57x 11.77x 11.68x 11.19x 11.12x

High 12.79x 12.37x 14.29x 12.01x 11.73x
Low 10.86x 10.99x 9.29x 10.11x 10.59x
Close 11.32x 12.32x 10.33x 10.40x 11.21x

TEV/LTM EBIT Average 15.39x 15.44x 15.86x 16.20x 17.14x

High 17.58x 16.33x 17.06x 17.33x 18.17x
Low 13.95x 14.11x 13.41x 14.61x 15.34x
Close 14.53x 16.27x 14.94x 15.05x 17.35x

TEV/NTM EBIT Average 13.15x 13.60x 13.86x 13.65x 13.38x

High 14.44x 14.36x 16.16x 14.34x 14.32x
Low 12.18x 12.38x 11.39x 12.41x 12.60x
 Close 12.75x 14.30x 12.69x 12.97x 12.76x

P/LTM EPS Average 18.39x 14.51x 12.58x 12.71x 14.25x

High 22.82x 17.24x 14.40x 13.76x 15.55x
Low 15.84x 12.93x 9.94x 11.08x 11.96x
Close 16.62x 13.86x 11.39x 11.69x 14.53x

P/NTM EPS Average 14.08x 13.81x 13.02x 13.25x 12.79x

High 15.53x 14.24x 14.68x 14.43x 14.03x
Low 12.84x 13.22x 10.29x 11.46x 12.09x
Close 13.77x 14.17x 11.78x 12.21x 12.43x

P/LTM Normalized EPS Average 22.34x 21.34x 21.25x 21.65x 22.31x

High 26.16x 22.13x 23.14x 23.31x 23.72x
Low 19.95x 20.21x 17.22x 19.19x 20.23x
Close 20.93x 22.02x 19.72x 19.77x 22.14x

P/BV Average 3.60x 3.32x 3.09x 3.09x 3.18x

High 4.20x 3.59x 3.46x 3.38x 3.36x
Low 3.20x 3.11x 2.50x 2.74x 2.86x
Close 3.36x 3.33x 2.86x 2.79x 3.17x

P/Tangible BV Average NM NM NM NM NM
High NM NM NM NM NM
Low NM NM NM NM NM
Close NM NM NM NM NM

P/NTM CFPS Average 12.66x 14.23x 13.83x 13.80x 16.73x

High 14.76x 15.43x 15.76x 14.76x 20.33x
Low 11.01x 12.19x 11.03x 12.42x 12.97x
Close 12.62x 14.89x 12.89x 12.68x 15.21x

TEV/LTM Unlevered FCF Average 45.25x 29.03x 15.34x 11.94x 21.05x

High 46.97x 46.84x 21.16x 13.22x 26.22x
Low 43.57x 19.36x 10.41x 10.77x 11.15x
Close 45.39x 20.50x 11.59x 10.95x 25.04x

Market Cap/LTM Levered FCF Average 46.26x 28.05x 13.42x 10.32x 18.53x
High 48.54x 48.37x 19.05x 11.54x 23.36x
 Low 44.42x 17.11x 8.58x 9.15x 9.56x
Close 46.62x 18.34x 9.83x 9.34x 22.05x

Average multiples are calculated using positive close values on each trading day within the frequency periods selected. Negative values are excluded from the calculation. When the Multiples are not meaningful, due to neg

When a mismatch exists between the currency of the equity listing and the reported financial results such results are translated into the currency of the listing at the exchange rate applicable on the financial period end date

Historical Equity Pricing Data supplied by Interactive Data Pricing and

Reference Data LLC
Dec-31-2020 Mar-12-2021
5.37x 5.47x
5.95x 5.90x
5.11x 5.16x
5.29x 5.35x

5.37x 4.37x
6.07x 5.38x
4.83x 3.50x
5.35x 3.61x

13.30x 14.25x
14.82x 16.07x
12.57x 12.89x
13.18x 14.05x

12.18x 10.87x
14.53x 12.99x
10.79x 8.82x
12.72x 9.15x

18.03x 20.54x
20.05x 23.72x
17.15x 17.45x
17.83x 21.50x

14.61x 12.84x
18.11x 15.85x
12.30x 10.95x
15.56x 11.44x

21.84x 26.16x
27.67x 28.22x
14.32x 23.28x
23.93x 28.17x

13.20x 11.13x
15.17x 13.46x
11.60x 10.04x
13.15x 10.45x

22.91x 25.88x
25.79x 28.91x
21.82x 21.69x
22.30x 28.91x

3.22x 3.04x
3.62x 3.22x
3.05x 2.87x
3.13x 3.08x

NM NM
NM NM
NM NM
NM NM

14.74x 12.81x
15.97x 17.50x
13.12x 10.22x
14.99x 17.50x

25.22x 19.31x
25.84x 19.65x
24.75x 18.95x
NM 19.65x

22.26x 18.19x
22.94x 18.56x
 21.73x 17.80x
NM 18.56x

ul, due to negative values, then they will not be displayed in the chart.

riod end date.

Pfizer Inc. (NYSE:PFE) > Financials > Historical Capitalization

In Millions of the trading currency, except per share items. Frequency: Quarterly Order: Latest on Right
Currency: Trading Currency Conversion: Today's Spot Rate
Units: S&P Capital IQ (Defaul Decimals: Capital IQ (Default)
Dilution: Basic

Historical Capitalization
Balance Sheet as of:
Sep-29-2019 Dec-31-2019 Mar-29-2020 Jun-28-2020 Sep-27-2020 Dec-31-2020
Pricing as of* Nov-07-2019 Feb-27-2020 May-07-2020 Aug-06-2020 Nov-05-2020 Feb-25-2021
Currency USD USD USD USD USD USD
Capitalization Detail
Share Price $36.91 $34.1 $36.96 $38.27 $36.39 $33.82
Shares Out. 5,534.1 5,547.6 5,554.8 5,556.9 5,558.4 5,579.3

Market Capitalization 204,264.5 189,174.5 205,306.7 212,661.8 202,270.1 188,692.9

- Cash & Short Term Investments 9,146.0 9,883.0 10,365.0 11,399.0 10,515.0 12,239.0
+ Total Debt 53,979.0 53,474.0 52,288.0 63,613.0 63,148.0 41,271.0
+ Pref. Equity 18.0 17.0 17.0 - - -
+ Total Minority Interest 293.0 303.0 312.0 228.0 236.0 235.0
= Total Enterprise Value (TEV) 249,408.5 233,085.5 247,558.7 265,103.8 255,139.1 217,959.9

Book Value of Common Equity 65,084.0 63,126.0 65,009.0 64,336.0 65,259.0 63,238.0
+ Pref. Equity 18.0 17.0 17.0 - - -
+ Total Minority Interest 293.0 303.0 312.0 228.0 236.0 235.0
+ Total Debt 53,979.0 53,474.0 52,288.0 63,613.0 63,148.0 41,271.0
= Total Capital 119,374.0 116,920.0 117,626.0 128,177.0 128,643.0 104,744.0

sheet components from the original filing that is publicly available as of

a given capitalization.
market pricing date and does click
Please not use
on restated
the valuebalance sheet
to see the data from
detailed
calculation. Prices shown on this page are the close price of the

Historical Equity Pricing Data supplied by Interactive Data Pricing and

Reference Data LLC
Pfizer Inc. (NYSE:PFE) > Financials > Capital Structure Summary
In Millions of the reported currency, except ratios and % of Total
values. Restatement: Latest Filings Period Type: Annual
Currency: Reported Currency Conversion: Today's Spot Rate
Units: S&P Capital IQ (Defaul Decimals: Capital IQ (Default)
Order: Latest on Right

Capital Structure Data

For the Fiscal Period Ending
12 months Dec-31-2018 12 months Dec-31-2019 12 months Dec-31-2020
Currency USD USD USD
Units Millions % of Total Millions % of Total Millions % of Total

Total Debt 42,123.0 39.8% 53,449.0 45.7% 41,271.0 39.4%

Total Common Equity 63,388.0 59.9% 63,126.0 54.0% 63,238.0 60.4%
Total Preferred Equity 19.0 0.0% 17.0 0.0% - -
Total Minority Interest 351.0 0.3% 303.0 0.3% 235.0 0.2%
Total Capital 105,881.0 100.0% 116,895.0 100.0% 104,744.0 100.0%

Currency USD USD USD

Exchange Rate 1.0 1.0 1.0
Conversion Method S S S

Debt Summary Data

For the Fiscal Period Ending
12 months Dec-31-2018 12 months Dec-31-2019 12 months Dec-31-2020
Currency USD USD USD
Units Millions % of Total Millions % of Total Millions % of Total

Total Commercial Paper 3,100.0 7.4% 13,915.0 26.0% 556.0 1.3%

Total Revolving Credit 0 0.0% 0 0.0% 0 0.0%
Total Term Loans - - - - 600.0 1.5%
Total Senior Bonds and Notes 37,340.0 88.6% 36,279.0 67.9% 5,250.0 12.7%
Total Lease Liabilities - - 1,299.0 2.4% 1,435.0 3.5%
General/Other Borrowings 973.0 2.3% 865.0 1.6% 32,073.0 77.7%
Total Principal Due 41,413.0 98.3% 52,358.0 98.0% 39,914.0 96.7%
Total Adjustments 710.0 1.7% 1,091.0 2.0% 1,357.0 3.3%
Total Debt Outstanding 42,123.0 100.0% 53,449.0 100.0% 41,271.0 100.0%

Available Credit
Undrawn Revolving Credit 7,000.0 - - - 11,332.0 -
Total Undrawn Credit 7,000.0 - - - 11,332.0 -

Additional Totals
Total Cash & ST Investments 18,930.0 - 9,699.0 - 12,239.0 -
Net Debt 23,193.0 - 43,750.0 - 29,032.0 -
Total Senior Debt 41,413.0 98.3% 52,358.0 98.0% 39,914.0 96.7%
Total Short-Term Borrowings 4,055.0 9.6% 14,733.0 27.6% 701.0 1.7%
Curr. Port. of LT Debt/Cap. Leases 4,781.0 11.4% 1,731.0 3.2% 2,323.0 5.6%
Long-Term Debt (Incl. Cap. Leases) 33,287.0 79.0% 36,985.0 69.2% 38,247.0 92.7%
Total Bank Debt 0 0.0% 0 0.0% 600.0 1.5%
Total Secured Debt - - 1,299.0 2.4% 1,435.0 3.5%
Total Senior Secured Debt - - 1,299.0 2.4% 1,435.0 3.5%
Total Unsecured Debt 41,413.0 98.3% 51,059.0 95.5% 38,479.0 93.2%
Senior Unsecured Bonds and Notes 37,340.0 88.6% 36,279.0 67.9% 5,250.0 12.7%
Fixed Rate Debt 34,209.9 81.2% 34,675.5 64.9% 5,250.0 12.7%
Variable Rate Debt 1,731.2 4.1% 300.0 0.6% - -
Zero Coupon Debt 1,145.0 2.7% 1,122.2 2.1% - -
Hedging Activities 857.0 2.0% 1,310.0 2.5% 1,566.0 3.8%

Credit Ratios
Net Debt/EBITDA 1.7x - 2.9x - 1.9x -
Total Debt/EBITDA 3.1x - 3.6x - 2.6x -
Total Senior Debt/EBITDA 3.1x - 3.5x - 2.5x -
Total Senior Secured/EBITDA - - 0.1x - 0.1x -
Net Debt/(EBITDA-CAPEX) 2.0x - 3.4x - 2.2x -
Total Debt/(EBITDA-CAPEX) 3.7x - 4.2x - 3.1x -
Total Senior Debt/(EBITDA-CAPEX) 3.6x - 4.1x - 3.0x -
Total Senior Secured/(EBITDA-CAPEX) - - 0.1x - 0.1x -

Fixed Payment Schedule

LT Debt (Incl. Cap. Leases) Due +1 4,776.0 11.3% 1,462.0 2.7% 2,002.0 4.9%
LT Debt (Incl. Cap. Leases) Due +2 2,967.5 7.0% 2,384.5 4.5% 2,173.0 5.3%
LT Debt (Incl. Cap. Leases) Due +3 2,967.5 7.0% 2,384.5 4.5% 2,173.0 5.3%
LT Debt (Incl. Cap. Leases) Due +4 2,033.5 4.8% 2,637.0 4.9% 1,534.0 3.7%
LT Debt (Incl. Cap. Leases) Due +5 2,033.5 4.8% 2,637.0 4.9% 1,534.0 3.7%
LT Debt (Incl. Cap. Leases) Due, Next 5 Yrs 14,778.0 35.1% 11,505.0 21.5% 9,416.0 22.8%
LT Debt (Incl. Cap. Leases) Due, After 5 Yrs 22,907.0 54.4% 25,912.0 48.5% 29,719.0 72.0%

Operating Lease Commitment Due +1 300.0 - 323.0 - 357.0 -

Operating Lease Commitment Due +2 252.0 - 286.0 - 299.0 -
Operating Lease Commitment Due +3 210.0 - 220.0 - 250.0 -
Operating Lease Commitment Due +4 267.0 - 180.0 - 167.0 -
Operating Lease Commitment Due +5 248.0 - 97.0 - 137.0 -
Operating Lease Commitment Due, Next 5 Yrs 1,277.0 - 1,106.0 - 1,210.0 -
Operating Lease Commitment Due, After 5 Yrs 2,040.0 - 424.0 - 408.0 -

Contractual Obligations Due +1 3,998.0 - 3,271.0 - 3,362.0 -

Contractual Obligations Due + 2 3,099.0 - 2,964.5 - 3,183.5 -
Contractual Obligations Due + 3 3,099.0 - 2,964.5 - 3,183.5 -
Contractual Obligations Due + 4 2,495.5 - 2,902.0 - 3,734.5 -
Contractual Obligations Due + 5 2,495.5 - 2,902.0 - 3,734.5 -
Contractual Obligations Due, Next 5 Yrs 15,187.0 - 15,004.0 - 17,198.0 -
Contractual Obligations Due, After 5 Yrs 23,032.0 - 21,445.0 - 18,828.0 -
Total Contractual Obligations 38,219.0 - 36,449.0 - 36,026.0 -

Interest Rate Data

Filing Date Feb-25-2021 - Feb-25-2021 - Feb-25-2021 -

Currency USD USD USD

Exchange Rate 1.0 1.0 1.0
Conversion Method S S S
Pfizer Inc. (NYSE:PFE) > Financials > Capital Structure Details
Principal Due in Millions of the
reported currency. Period Type: Annual Source: A 2020 filed Feb-25-2021
Currency: Reported Currency Conversion: Today's Spot Rate
Units: S&P Capital IQ (Default) Decimals: Capital IQ (Default)

FY 2020 (Dec-31-2020) Capital Structure As Reported Details

Coupon/Base
Description Type Principal Due (USD) Rate Floating Rate Maturity Seniority Secured
0.800% Senior Unsecured Bonds and Notes 750.0 0.800% NA May-28-2025 Senior No
Notes
1.700% Senior Unsecured Bonds and Notes 1,000.0 1.700% NA May-28-2030 Senior No
Notes
2.550% Senior Unsecured Bonds and Notes 1,000.0 2.550% NA May-28-2040 Senior No
Notes
2.625% Senior Unsecured Bonds and Notes 1,250.0 2.625% NA Apr-01-2030 Senior No
Notes
2.700% Senior Unsecured Bonds and Notes 1,250.0 2.700% NA May-28-2050 Senior No
Notes
Commercial Paper Commercial Paper 556.0 0.130% NA Dec-31-2021 Senior No
Delayed Draw Term Loan Term Loans 600.0 NA NA - Senior No
Agreement
Lines of Credit Revolving Credit - NA NA - Senior No
Long-Term Debt-Other Other Borrowings 31,924.0 NA NA - Senior No
Operating Lease Liabilities Capital Lease 1,435.0 2.900% NA - Senior Yes
Other Long-Term Debt Other Borrowings 4.0 NA NA - Senior No
Other Short-Term Borrowings Other Borrowings 145.0 NA NA Dec-31-2021 Senior No
Revolving Credit Facilities Revolving Credit - NA NA 2024 Senior No
Revolving Credit Facilities Revolving Credit - NA NA Sep-01-2021 Senior No

FY 2019 (Dec-31-2019) Capital Structure As Reported Details

Coupon/Base
Description Type Principal Due (USD) Rate Floating Rate Maturity Seniority Secured
2.800% Notes * Bonds and Notes 500.0 2.800% NA Mar-11-2022 Senior No
2.950% Notes * Bonds and Notes 750.0 2.950% NA Mar-15-2024 Senior No
3.250% Senior Unsecured Bonds and Notes 1,349.0 3.250% NA Feb-01-2023 Senior No
Notes
3.450%* Notes * Bonds and Notes 1,750.0 3.450% NA Mar-15-2029 Senior No
3.900% Notes * Bonds and Notes 750.0 3.900% NA Mar-15-2039 Senior No
4.000% Notes * Bonds and Notes 1,250.0 4.000% NA Mar-15-2049 Senior No
4.30% Senior Unsecured Notes Bonds and Notes 750.0 4.300% NA Jun-01-2043 Senior No
*4.4% Senior Unsecured Notes Bonds and Notes 1,000.0 4.400% NA May-15-2044 Senior No
*4.700% Senior Unsecured Bonds and Notes 1,142.0 4.700% NA Feb-01-2043 Senior No
Notes *
5.20% Notes * Bonds and Notes 391.0 5.200% NA 2020 Senior No
5.60% Notes * Bonds and Notes 539.0 5.600% NA 2040 Senior No
5.80% Notes * Bonds and Notes 408.0 5.800% NA 2023 Senior No
Commercial Paper Commercial Paper 13,915.0 0.130% NA Dec-31-2021 Senior No
Lines of Credit Revolving Credit - NA NA - Senior No
Notes 1.95% - June 2021 * Bonds and Notes 1,150.0 1.950% NA Jun-03-2021 Senior No
Notes 2.75% - June 2026 * Bonds and Notes 1,250.0 2.750% NA Jun-03-2026 Senior No
Notes 3.00% - June 2023 * Bonds and Notes 1,000.0 3.000% NA Jun-01-2023 Senior No
Notes 3.40% - May 2024 * Bonds and Notes 1,000.0 3.400% NA May-01-2024 Senior No
Notes 5.95% - April 2037 * Bonds and Notes 2,000.0 5.950% NA Apr-01-2037 Senior No
Notes 7.20% - March 2039 * Bonds and Notes 2,500.0 7.200% NA Mar-01-2039 Senior No
Notes Due 2022 * Bonds and Notes 1,145.0 0.250% NA Mar-06-2022 Senior No
Operating Lease Liabilities Capital Lease 1,299.0 2.900% NA - Senior Yes
Other Long-Term Debt Other Borrowings 5.0 NA NA - Senior No
Other Notes * Bonds and Notes 181.3 NA NA - Senior No
Other Short-Term Borrowings Other Borrowings 860.0 NA NA Dec-31-2021 Senior No
Revolving Credit Facilities Revolving Credit - NA NA Sep-01-2021 Senior No
Revolving Credit Facilities Revolving Credit - NA NA 2024 Senior No
Senior Unsecured Notes * Bonds and Notes 1,000.0 4.200% NA Sep-15-2048 Senior No
Senior Unsecured Notes * Bonds and Notes 700.0 4.100% NA Sep-01-2028 Senior No
Senior Unsecured Notes * Bonds and Notes 1,000.0 3.600% NA Sep-15-2028 Senior No
Senior Unsecured Notes * Bonds and Notes 1,000.0 3.200% NA Sep-15-2023 Senior No
Senior Unsecured Notes * Bonds and Notes 300.0 NA LIBOR + 0.330% Sep-15-2023 Senior No
Senior Unsecured Notes * Bonds and Notes 1,000.0 3.000% NA Sep-15-2021 Senior No
Senior Unsecured Notes - EUR Bonds and Notes 1,122.2 NA NA Mar-06-2020 Senior No
*Senior Unsecured Notes - EUR Bonds and Notes 841.7 1.000% NA Mar-06-2027 Senior No
*Senior Unsecured Notes Due Bonds and Notes 1,000.0 2.200% NA Dec-15-2021 Senior No
2021
Senior* Unsecured Notes Due Bonds and Notes 1,750.0 3.000% NA Dec-15-2026 Senior No
2026
Senior* Unsecured Notes Due Bonds and Notes 1,000.0 4.000% NA Dec-15-2036 Senior No
2036
Senior* Unsecured Notes Due Bonds and Notes 622.5 6.500% NA Jun-03-2038 Senior No
2038
Senior* Unsecured Notes Due Bonds and Notes 1,822.4 2.735% NA Jun-15-2043 Senior No
2043
Senior* Unsecured Notes Due Bonds and Notes 1,250.0 4.125% NA Dec-15-2046 Senior No
2046
Senior* Unsecured Notes Due Bonds and Notes 1,065.0 4.200% NA Mar-17-2047 Senior No
2047
 nt
Convertible Currency
No USD
No USD
No USD
No USD
No USD
No USD
No USD
No USD
No USD
No USD
No USD
No USD
No USD
No USD

nt
Convertible Currency
No USD
No USD
No USD
No USD
No USD
No USD
No USD
No USD
No USD
No USD
No USD
No USD
No USD
No USD
No USD
No USD
No USD
No USD
No USD
No USD
No EUR
No USD
No USD
No USD
No USD
No USD
No USD
No USD
No USD
No USD
No USD
No USD
No USD
No EUR
No EUR
No USD
No USD
No USD
No GBP
No GBP
No USD
No USD
Pfizer Inc. (NYSE:PFE) > Financials > Ratios

Restatement: Latest Filings Period Type: Annual

Order: Latest on Right Decimals: Capital IQ (Default)
Source: Capital IQ & Proprietar

Ratios
For the Fiscal Period Ending
12 months 12 months 12 months 12 months 12 months 12 months
Profitability
Return on Assets % 5.1% 5.2% 5.4% 2.8% 3.2% 3.9%
Return on Capital % 8.1% 8.6% 8.5% 4.2% 4.7% 5.7%
Return on Equity % 10.2% 11.6% 32.5% 5.7% 17.1% 11.1%
Return on Common Equity % 10.2% 11.6% 32.6% 5.7% 17.1% 11.1%

Margin Analysis
Gross Margin % 80.8% 77.4% 79.4% 78.3% 80.5% 79.5%
SG&A Margin % 29.3% 28.2% 27.8% 29.8% 30.5% 26.0%
EBITDA Margin % 38.5% 37.2% 39.8% 33.0% 34.3% 35.5%
EBITA Margin % 35.9% 34.4% 37.1% 29.6% 31.2% 32.4%
EBIT Margin % 28.2% 26.7% 28.0% 18.0% 20.4% 24.2%
Earnings from Cont. Ops Margin % 14.3% 13.7% 40.6% 9.5% 26.4% 16.8%
Net Income Margin % 14.2% 13.7% 40.6% 27.3% 39.5% 22.9%
Net Income Avail. for Common Margin % 14.2% 13.6% 40.5% 9.4% 26.3% 16.7%
Normalized Net Income Margin % 19.2% 17.3% 17.4% 11.6% 13.1% 16.2%
Levered Free Cash Flow Margin % 28.3% 24.5% 25.3% 3.2% 33.9% 25.1%
Unlevered Free Cash Flow Margin % 29.8% 25.9% 26.8% 5.2% 36.2% 27.2%

Asset Turnover
Total Asset Turnover 0.3x 0.3x 0.3x 0.2x 0.3x 0.3x
Fixed Asset Turnover 3.8x 3.9x 3.9x 3.0x 3.0x 2.8x
Accounts Receivable Turnover 5.9x 6.4x 6.4x 5.0x 5.6x 5.7x
Inventory Turnover 1.4x 1.7x 1.5x 1.2x 1.1x 1.1x

Short Term Liquidity

Current Ratio 1.5x 1.3x 1.4x 1.6x 0.9x 1.4x
Quick Ratio 1.2x 0.9x 1.0x 1.0x 0.5x 0.9x
Cash from Ops. to Curr. Liab. 0.5x 0.5x 0.6x 0.5x 0.3x 0.6x
 Avg. Days Sales Out. 61.9 56.8 57.1 72.6 65.6 64.2
Avg. Days Inventory Out. 256.9 219.5 242.1 310.3 330.7 322.6
Avg. Days Payable Out. 111.2 133.4 144.4 193.4 205.5 157.0
Avg. Cash Conversion Cycle 207.6 142.9 154.9 189.5 190.8 229.8

Long Term Solvency

Total Debt/Equity 60.1% 70.6% 60.9% 66.1% 84.2% 65.0%
Total Debt/Capital 37.5% 41.4% 37.9% 39.8% 45.7% 39.4%
LT Debt/Equity 44.4% 52.7% 47.1% 52.2% 58.3% 60.3%
LT Debt/Capital 27.8% 30.9% 29.2% 31.4% 31.6% 36.5%
Total Liabilities/Total Assets 61.2% 65.1% 58.3% 60.0% 62.1% 58.8%

EBIT / Interest Exp. 11.5x 11.9x 11.6x 5.6x 5.3x 7.0x

EBITDA / Interest Exp. 15.7x 16.6x 16.4x 10.2x 9.4x 10.8x
(EBITDA-CAPEX) / Interest Exp. 14.5x 15.0x 14.9x 8.7x 8.1x 9.3x
Total Debt/EBITDA 2.1x 2.1x 2.1x 3.1x 3.6x 2.6x
Net Debt/EBITDA 0.8x 1.2x 1.1x 1.7x 2.9x 1.9x
Total Debt/(EBITDA-CAPEX) 2.2x 2.4x 2.3x 3.7x 4.2x 3.1x
Net Debt/(EBITDA-CAPEX) 0.9x 1.4x 1.2x 2.0x 3.4x 2.2x

Altman Z Score 2.49 2.3 2.58 2.77 2.48 2.78

Growth Over Prior Year

Total Revenue (1.5%) 8.1% (0.5%) (22.3%) 0.8% 1.8%
Gross Profit (2.7%) 3.6% 2.0% (23.4%) 3.7% 0.6%
EBITDA (10.1%) 4.4% 6.3% (35.5%) 5.0% 5.3%
EBITA (11.1%) 3.6% 7.2% (37.9%) 6.2% 5.6%
EBIT (12.0%) 2.2% 4.3% (50.0%) 13.9% 20.9%
Earnings from Cont. Ops. (23.5%) 3.7% 195.3% (81.9%) 181.5% (35.4%)
Net Income (23.8%) 3.7% 195.3% (47.7%) 45.9% (40.9%)
Normalized Net Income (8.9%) (2.5%) (0.0%) (48.2%) 13.5% 26.7%
Diluted EPS before Extra (21.5%) 5.3% 200.6% (81.8%) 198.4% (35.1%)

Accounts Receivable (2.7%) 0.6% (0.0%) (2.4%) (15.6%) 17.1%

Inventory 32.7% (9.7%) 11.7% (0.9%) (5.9%) 13.8%
Net PP&E 17.0% (3.3%) 4.1% (3.5%) 6.5% 7.3%
Total Assets (0.1%) 2.5% 0.1% (7.2%) 5.1% (8.0%)

Tangible Book Value NM NM NM NM NM NM

 Common Equity (9.2%) (8.0%) 19.8% (11.1%) (0.4%) 0.2%
Cash from Ops. (14.0%) 10.2% 3.8% (5.8%) (20.5%) 14.4%
Capital Expenditures 16.5% 30.5% 7.3% 1.4% 4.4% 8.7%
Levered Free Cash Flow (17.7%) (6.2%) 2.6% (90.3%) 980.1% (24.7%)
Unlevered Free Cash Flow (17.4%) (5.9%) 2.8% (85.0%) 606.1% (23.6%)
Dividend per Share 7.7% 7.1% 6.7% 6.3% 5.9% 5.6%

Compound Annual Growth Rate Over Two Years

Total Revenue (2.7%) 3.2% 3.7% (12.1%) (11.5%) 1.3%
Gross Profit (3.4%) 0.4% 2.8% (11.6%) (10.9%) 2.1%
EBITDA (9.8%) (3.1%) 5.3% (17.2%) (17.7%) 5.1%
EBITA (10.0%) (4.0%) 5.4% (18.4%) (18.8%) 5.9%
EBIT (10.0%) (5.1%) 3.3% (27.8%) (24.5%) 17.4%
Earnings from Cont. Ops. (21.8%) (11.0%) 75.0% (26.9%) (28.7%) 34.8%
Net Income (43.8%) (11.1%) 75.0% 24.3% (12.6%) (7.1%)
Normalized Net Income (4.4%) (5.8%) (1.3%) (28.0%) (23.3%) 19.9%
Diluted EPS before Extra (17.8%) (9.0%) 78.0% (26.0%) (26.3%) 39.2%

Accounts Receivable (6.5%) (1.1%) 0.3% (1.2%) (9.2%) (0.6%)

Inventory 10.4% 9.4% 0.4% 5.2% (3.4%) 3.5%
Net PP&E 5.4% 6.4% 0.4% 0.3% 1.4% 6.9%
Total Assets (1.4%) 1.2% 1.3% (3.6%) (1.2%) (1.6%)

Tangible Book Value NM NM NM NM NM NM

Common Equity (7.9%) (8.6%) 5.0% 3.2% (5.9%) (0.1%)
Cash from Ops. (8.9%) (2.6%) 7.0% (1.1%) (13.4%) (4.6%)
Capital Expenditures 7.6% 23.3% 18.3% 4.3% 2.9% 6.5%
Levered Free Cash Flow (12.0%) (12.1%) (1.9%) (68.4%) 2.4% 185.3%
Unlevered Free Cash Flow (11.8%) (11.8%) (1.6%) (60.7%) 2.9% 132.3%
Dividend per Share 8.0% 7.4% 6.9% 6.5% 6.1% 5.7%

Compound Annual Growth Rate Over Three Years

Total Revenue (3.7%) 0.8% 1.9% (5.8%) (8.0%) (7.3%)
Gross Profit (4.4%) (1.1%) 0.9% (6.8%) (6.8%) (7.2%)
EBITDA (9.5%) (5.3%) (0.1%) (10.6%) (10.4%) (10.7%)
EBITA (9.5%) (5.7%) (0.4%) (11.6%) (10.9%) (11.3%)
EBIT (9.1%) (6.1%) (2.1%) (18.9%) (15.9%) (11.7%)
Earnings from Cont. Ops. (8.2%) (14.1%) 32.8% (17.9%) 14.5% (31.0%)
Net Income (21.8%) (31.0%) 32.6% 17.0% 31.1% (23.3%)
 Normalized Net Income (5.5%) (3.8%) (3.9%) (20.4%) (16.2%) (9.3%)
Diluted EPS before Extra (2.5%) (10.7%) 35.5% (16.8%) 17.7% (29.4%)

Accounts Receivable (8.5%) (4.2%) (0.7%) (0.6%) (6.3%) (1.2%)

Inventory 7.3% 3.2% 10.2% (0.0%) 1.4% 2.0%
Net PP&E 1.4% 2.4% 5.6% (0.9%) 2.3% 3.3%
Total Assets (3.4%) (0.1%) 0.8% (1.6%) (0.8%) (3.5%)

Tangible Book Value NM NM NM NM NM NM

Common Equity (7.3%) (7.9%) 0.0% (0.7%) 2.0% (3.9%)
Cash from Ops. (4.3%) (2.9%) (0.6%) 2.5% (8.1%) (5.0%)
Capital Expenditures 1.7% 14.8% 17.7% 12.4% 4.4% 4.8%
Levered Free Cash Flow (5.9%) (10.1%) (7.5%) (54.6%) 2.5% (7.5%)
Unlevered Free Cash Flow (6.0%) (9.8%) (7.2%) (47.4%) 2.9% (6.8%)
Dividend per Share 8.4% 7.7% 7.2% 6.7% 6.3% 5.9%

Compound Annual Growth Rate Over Five Years

Total Revenue (5.6%) (2.8%) (0.8%) (4.6%) (3.7%) (3.0%)
Gross Profit (5.0%) (3.7%) (1.6%) (5.5%) (4.0%) (3.3%)
EBITDA (5.7%) (5.6%) (3.8%) (10.3%) (7.6%) (4.6%)
EBITA (5.4%) (5.5%) (3.8%) (11.0%) (8.2%) (5.0%)
EBIT (4.7%) (5.2%) (4.3%) (15.4%) (11.8%) (6.0%)
Earnings from Cont. Ops. (3.5%) (1.7%) 18.8% (19.5%) 3.6% 0.1%
Net Income (3.4%) (6.3%) 7.9% (12.7%) 12.2% 6.7%
Normalized Net Income (2.3%) (3.3%) (3.8%) (14.3%) (12.2%) (6.2%)
Diluted EPS before Extra 1.6% 3.3% 24.0% (17.2%) 6.2% 2.2%

Accounts Receivable (9.4%) (8.8%) (5.1%) (3.0%) (4.2%) (0.6%)

Inventory (1.9%) 0.5% 4.5% 4.0% 4.5% 1.4%
Net PP&E (5.9%) (3.5%) 1.0% 1.5% 3.9% 2.1%
Total Assets (3.0%) (1.8%) (1.6%) (1.5%) 0.0% (1.6%)

Tangible Book Value NM NM NM NM NM NM

Common Equity (5.9%) (6.2%) (2.6%) (3.6%) (2.4%) (0.5%)
Cash from Ops. 5.1% (4.4%) 0.1% (2.2%) (5.9%) (0.4%)
Capital Expenditures (1.6%) 1.9% 8.1% 10.5% 11.6% 10.0%
Levered Free Cash Flow 5.9% (5.6%) (4.3%) (40.8%) (3.6%) (5.3%)
Unlevered Free Cash Flow 4.9% (5.7%) (4.3%) (35.3%) (3.3%) (4.8%)
Dividend per Share 9.2% 8.4% 7.8% 7.2% 6.7% 6.3%
Pfizer Inc. (NYSE:PFE) > Financials > Supplemental

In Millions of the reported currency, except per share items. Restatement: Latest Filings Period Type: Annual
Currency: Reported Currency Conversion: Today's Spot Rate
Order: Latest on Right Units: S&P Capital IQ (Default)
Decimals: Capital IQ (Default) Source: Capital IQ & Proprietary Data

Supplemental
For the Fiscal Period Ending
12 months 12 months 12 months 12 months 12 months 12 months
Currency USD USD USD USD USD USD
Options Outstanding
Options Out. at the Beginning of the Period - - - - - 88.6
Options Granted During the Period - - - - - 5.8
Options Exercised During the Period - - - - - 18.5
Options Cancelled During the Period - - - - - 0.5
Options Out. at the End of the Period - - - - - 75.4
W/Avg. Strike Price of Out. at the End of the Period - - - - - $28.31
W/Avg. Strike Price of Granted - - - - - $29.91

Options Outstanding - All Classes

Options Out. at the Beginning of the Period - - - - - 88.6
Options Granted During the Period - - - - - 5.8
Options Exercised During the Period - - - - - 18.5
Options Cancelled During the Period - - - - - 0.5
Options Out. at the End of the Period - - - - - 75.4

Stock Based Compensation

Restr. Stock Comp. Exp., Before Tax 306.0 299.0 301.0 286.0 275.0 272.0
Stock Options Comp. Exp., Before Tax 165.0 106.0 55.0 12.0 7.0 6.0
Stock Based Comp. Exp., Before Tax 677.0 700.0 851.0 941.0 708.0 776.0
Stock Based Comp. Exp. Tax Effect (198.0) (205.0) (163.0) (180.0) (137.0) (141.0)
Stock Based Comp. Exp., After Tax 471.0 486.0 677.0 769.0 581.0 639.0

Adoption of FIN 48 Related Items

Unrecognized Tax Benefits - Beginning of Period 6,182.0 5,919.0 5,826.0 6,558.0 6,259.0 5,381.0
Increase in Unrecog. Tax Benefits - Current Yr. 675.0 489.0 753.0 370.0 383.0 411.0
Increase in Unrecog. Tax Benefits - Prior Yrs. 31.0 11.0 49.0 192.0 36.0 232.0
Decrease in Unrecog. Tax Benefits - Prior Yrs. (496.0) (409.0) (28.0) (561.0) (1,109.0) (64.0)
Settlements with Tax Authorities (64.0) (126.0) (35.0) (123.0) (100.0) (15.0)
Unrecog. Tax Benefits - Other Adjustments (408.0) (58.0) (7.0) (177.0) (88.0) (350.0)
Unrecognized Tax Benefits - End of Period 5,919.0 5,826.0 6,558.0 6,259.0 5,381.0 5,595.0

Interest and Penalties Recog. on IS - Before Tax 71.0 72.0 208.0 103.0 (564.0) 89.0
Interest and Penalties Recog. on BS - Before Tax - - - - 485.0 493.0

Changes in Unrecog. Tax Benefit w/in 1 Year - Max - - - - - (50.0)

Unrecog. Tax Benefit Impacting Effective Tax Rate - - - - - 5.6

Capitalized Interest Data

Interest Capitalized 32.0 61.0 72.0 73.0 88.0 96.0
Interest Capitalized, Expensed 25.0 - - - - -

Fair Value Measurements

Level 1 Assets - Quoted Prices - 794.0 1,523.0 1,260.0 1,863.0 2,776.0
Level 2 Assets - Observable Prices 1,388.0 21,403.0 23,414.0 18,850.0 9,313.0 11,501.0
Level 3 Assets - Unobservable Prices 1,336.0 - - - - -
Fair Value of Assets 2,724.0 22,197.0 24,937.0 20,110.0 11,176.0 14,277.0

Level 2 Liabilities - Observable Prices 42,859.0 36,562.0 37,944.0 36,284.0 41,560.0 46,633.0
Fair Value of Liabilities 42,859.0 36,562.0 37,944.0 36,284.0 41,560.0 46,633.0

Filing Date Feb-22-2018 Feb-28-2019 Feb-27-2020 Feb-25-2021 Feb-25-2021 Feb-25-2021

Pfizer Inc. (NYSE:PFE) > Financials > Industry Specific

In Millions of the reported currency, except per share items. Restatement: Latest Filings Period Type: Annual
Currency: Reported Currency Conversion: Today's Spot Rate
Order: Latest on Right Units: S&P Capital IQ (Default)
Decimals: Capital IQ (Default) Source: Capital IQ & Proprietary Data

Industry Specific
For the Fiscal Period Ending
12 months 12 months 12 months 12 months 12 months 12 months
Currency USD USD USD USD USD USD
Pharmaceutical and Biotech Items
Number of Products in Clinical Development 90 96 87 100 95 95
Number of Products in Phase I 34 35 30 35 26 27
Number of Products in Phase II 18 20 18 28 37 35
Number of Products in Phase III 30 34 29 26 23 24
Number of Products in Pre-Registration 8 7 10 11 9 9
Number of Products Approved During the Period 1 5 12 8 8 13
Number of Products Launched During the Period 1 - - - - -

Filing Date Feb-22-2018 Feb-28-2019 Feb-27-2020 Feb-25-2021 Feb-25-2021 Feb-25-2021

Pfizer Inc. (NYSE:PFE) > Financials > Pension/OPEB

In Millions of the reported currency, except per share items. Restatement: Latest Filings Period Type: Annual
Currency: Reported Currency Conversion: Today's Spot Rate
Order: Latest on Right Units: S&P Capital IQ (Default)
Decimals: Capital IQ (Default) Source: Capital IQ & Proprietary Data

Pension/OPEB
For the Fiscal Period Ending
12 months 12 months 12 months 12 months 12 months 12 months
Currency USD USD USD USD USD USD
Pension Information - Total
Defined Benefit Net Periodic Cost
Def. Benefit Service Cost 495.0 440.0 464.0 136.0 125.0 146.0
Def. Benefit Plan Interest Cost 1,037.0 932.0 892.0 865.0 891.0 697.0
Def. Benefit Plan Return on Assets (1,507.0) (1,339.0) (1,350.0) (1,400.0) (1,207.0) (1,321.0)
Def. Benefit Plan Other Cost 1,178.0 663.0 690.0 399.0 523.0 548.0
Def. Benefit Plan Total Cost 1,203.0 696.0 695.0 (2.0) 331.0 70.0

Def. Contribution Plan Cost 287.0 317.0 380.0 622.0 659.0 685.0
Total Pension Expense 1,490.0 1,013.0 1,075.0 620.0 990.0 755.0

Defined Benefit Obligation

Beg. Def. Benefit Obligation 28,852.0 25,483.0 26,688.0 28,804.0 26,373.0 28,945.0
Def. Benefit Service Cost 495.0 440.0 464.0 136.0 125.0 146.0
Def. Benefit Interest Cost 1,037.0 932.0 892.0 865.0 891.0 697.0
Def. Benefit Employee Contributions 7.0 7.0 6.0 7.0 7.0 8.0
Def. Benefits Paid (866.0) (998.0) (932.0) (977.0) (978.0) (817.0)
Foreign Exchange Adj. (938.0) (781.0) 760.0 (457.0) (33.0) 646.0
Def. Benefit Settlement/Curtailment (2,625.0) (576.0) (960.0) (488.0) (798.0) (801.0)
Other Adj. To Def. Benefit Obligation (481.0) 2,179.0 1,888.0 (1,519.0) 3,356.0 1,483.0
Proj. Benefit Obligation (Pension) 25,483.0 26,688.0 28,804.0 26,373.0 28,945.0 30,307.0

Accum. Benefit Obligation 24,900.0 26,100.0 28,300.0 25,921.0 28,486.0 29,806.0

Plan Assets
Beg. Plan Assets 21,294.0 19,592.0 20,239.0 23,147.0 21,266.0 23,542.0
Actual Return on Plan Assets 166.0 1,632.0 2,816.0 (873.0) 3,633.0 2,842.0
Employer Contributions 1,716.0 1,360.0 1,398.0 838.0 385.0 1,629.0
Participant Contributions 7.0 7.0 6.0 7.0 7.0 8.0
Benefits Paid (866.0) (998.0) (932.0) (977.0) (978.0) (817.0)
Foreign Exchange Adjustments (602.0) (782.0) 561.0 (380.0) 42.0 462.0
Plan Settlement/Curtailment (2,626.0) (572.0) (971.0) (497.0) (796.0) (801.0)
Other Plan Adjustments 502.0 (1.0) 30.0 - (16.0) (963.0)
Total Plan Assets 19,592.0 20,239.0 23,147.0 21,266.0 23,542.0 25,905.0

Breakdown of Plan Assets

Plan Assets - Equities (%) 39.8% 38.1% 36.3% 28.1% 27.9% 25.6%
Plan Assets - Fixed Income (%) 39.7% 42.4% 44.0% 50.0% 50.5% 54.2%
Other Plan Assets (%) 20.5% 19.6% 19.7% 21.9% 21.6% 20.4%

Breakdown of Plan Assets

Plan Assets - Equities 7,796.4 7,701.0 8,405.4 5,966.2 6,563.9 6,621.2
Plan Assets - Fixed Income 7,785.4 8,574.0 10,177.8 10,640.8 11,892.3 14,028.4
Other Plan Assets 4,010.2 3,964.0 4,555.0 4,667.3 5,094.8 5,281.3

Weighted Avg. Assumptions on Def. Benefit Obligation

Rate of PBO Compensation Increase - Min - - - 1.4% 1.4% 2.9%
Rate of PBO Compensation Increase - Max - - - 1.4% 1.4% 2.9%

Estimated Future Benefits Paid

Est. Future Benefits Paid - 1st Yr 1,476.0 2,002.0 1,753.0 1,908.0 2,021.0 1,637.0
Est. Future Benefits Paid - 2nd Yr 2,124.0 1,519.0 1,573.0 1,582.0 1,560.0 1,532.0
Est. Future Benefits Paid - 3rd Yr 1,462.0 1,400.0 1,600.0 1,552.0 1,527.0 1,523.0
Est. Future Benefits Paid - 4th Yr 1,416.0 1,421.0 1,575.0 1,518.0 1,522.0 1,521.0
Est. Future Benefits Paid - 5th Yr 1,443.0 1,398.0 1,556.0 1,508.0 1,506.0 1,479.0
Est. Future Benefits Paid - Thereafter 6,988.0 6,761.0 7,479.0 7,350.0 7,186.0 7,135.0

Balance Sheet Reconciliation Items

Accrued Benefit Liability (151.0) (340.0) (186.0) (196.0) (219.0) (158.0)

Adj. for Liability Recognized on Balance Sheet

Net Asset/Liability Recognized on Balance Sheet (5,890.0) (6,448.0) (5,658.0) (5,107.0) (5,403.0) (4,402.0)

Other Compr. Income Components Recognized on the BS

Net Actuarial Loss/Gain 6,670.0 7,697.0 7,560.0 7,803.0 8,217.0 8,697.0
Prior Service Cost/Benefit 0 (15.0) (12.0) (2.0) 23.0 35.0
Net Amount Recognized 6,669.0 7,683.0 7,546.0 7,802.0 8,241.0 8,732.0

Consolidated Balance Sheet Amounts

Long Term Assets 572.0 300.0 454.0 401.0 453.0 522.0
Current Liabilities (151.0) (340.0) (186.0) (196.0) (219.0) (158.0)
Long Term Liabilities (6,309.0) (6,406.0) (5,926.0) (5,312.0) (5,637.0) (4,765.0)

Net Periodic Benefit Cost to be Recognized in the Subsequent Period

Prior Service Cost/Credit 2.0 0 (3.0) (7.0) (7.0) -
Net Actuarial Loss/Gain 526.0 577.0 238.0 238.0 265.0 -
Total Amount to be Recognized 528.0 577.0 235.0 232.0 259.0 -

Other Pension Related Items

Est. Contributions - Next Year 1,296.0 1,487.0 886.0 355.0 1,637.0 409.0
Benefit Info Date Dec-31-2015 Dec-31-2016 Dec-31-2017 Dec-31-2018 Dec-31-2019 Dec-31-2020

OPEB Information - Total

Defined Benefit Net Periodic Cost
Def. Benefit Service Cost 55.0 41.0 42.0 39.0 37.0 38.0
Def. Benefit Interest Cost 117.0 101.0 90.0 72.0 75.0 49.0
Def. Benefit Expected Return on Assets (53.0) (34.0) (36.0) (37.0) (33.0) (36.0)
Def. Benefit Other Cost (139.0) (168.0) (170.0) (186.0) (225.0) (170.0)
Def. Benefit Total Cost (21.0) (59.0) (75.0) (111.0) (146.0) (118.0)

Total OPEB Expense (21.0) (59.0) (75.0) (111.0) (146.0) (118.0)

Defined Benefit Obligation

Beg. Def. Benefit Obligation 3,168.0 2,463.0 2,254.0 2,028.0 1,870.0 1,667.0
Def. Benefit Service Cost 55.0 41.0 42.0 39.0 37.0 38.0
Def. Benefit Interest Cost 117.0 101.0 90.0 72.0 75.0 49.0
Def. Benefit Employee Contributions 79.0 85.0 94.0 102.0 84.0 88.0
Def. Benefits Paid (300.0) (282.0) (280.0) (249.0) (221.0) (201.0)
Foreign Exchange Adj. (20.0) - 5.0 (4.0) (1.0) 2.0
Def. Benefit Settlement/Curtailment (3.0) - 1.0 (1.0) - -
Other Adj. To Def. Benefit Obligation (633.0) (155.0) (176.0) (118.0) (177.0) (406.0)
Proj. Benefit Obligation 2,463.0 2,254.0 2,028.0 1,870.0 1,667.0 1,238.0

Accum. Benefit Obligation 2,463.0 2,254.0 2,028.0 1,870.0 1,667.0 1,238.0

Plan Assets
Beg. Plan Assets 762.0 622.0 458.0 494.0 469.0 519.0
Actual Return on Plan Assets (3.0) 44.0 39.0 (22.0) 50.0 69.0
Employer Contributions 84.0 - 183.0 145.0 137.0 113.0
Participant Contributions 79.0 85.0 94.0 102.0 84.0 88.0
Benefits Paid (300.0) (282.0) (280.0) (249.0) (221.0) (201.0)
Other Plan Adjustments - (12.0) - - - -
Total Plan Assets 622.0 458.0 494.0 469.0 519.0 588.0

Weighted Avg. Assumptions on Net Periodic Cost

Net Periodic Cost Disc. Rate - Min 4.2% 4.5% 4.2% 3.7% 4.3% 3.2%
Net Periodic Cost Disc. Rate - Max 4.2% 4.5% 4.2% 3.7% 4.3% 3.2%
Exp. Long-Term Rate of Return on Assets - Min 8.3% 8.0% 8.0% 7.5% 7.3% 7.0%
Exp. Long-Term Rate of Return on Assets - Max 8.3% 8.0% 8.0% 7.5% 7.3% 7.0%

Breakdown of Plan Assets

Plan Assets - Equities (%) 12.8% - - - - -
Plan Assets - Fixed Income (%) 12.2% - - - - -
Other Plan Assets (%) 75.0% 100.0% 100.0% 100.0% 100.0% 100.0%

Breakdown of Plan Assets

Plan Assets - Equities 79.6 - - - - -
Plan Assets - Fixed Income 75.9 - - - - -
Other Plan Assets 466.5 458.0 494.0 469.0 519.0 588.0

Weighted Avg. Assumptions on Def. Benefit Obligation

PBO Assumed Rate of Return - Min 4.5% 4.2% 3.7% 4.3% 3.2% 2.5%
PBO Assumed Rate of Return - Max 4.5% 4.2% 3.7% 4.3% 3.2% 2.5%

Estimated Future Benefits Paid

Est. Future Benefits Paid - 1st Yr 198.0 186.0 173.0 166.0 153.0 97.0
Est. Future Benefits Paid - 2nd Yr 205.0 196.0 179.0 171.0 137.0 94.0
Est. Future Benefits Paid - 3rd Yr 208.0 198.0 181.0 171.0 137.0 92.0
Est. Future Benefits Paid - 4th Yr 208.0 197.0 179.0 168.0 136.0 89.0
Est. Future Benefits Paid - 5th Yr 207.0 196.0 173.0 165.0 134.0 86.0
Est. Future Benefits Paid - Thereafter 1,001.0 919.0 802.0 777.0 642.0 430.0

Balance Sheet Reconciliation Items

Accrued Benefit Liability (31.0) (30.0) (31.0) (29.0) (24.0) (6.0)
Adj. for Liability Recognized on Balance Sheet
Net Asset/Liability Recognized on Balance Sheet (1,841.0) (1,796.0) (1,534.0) (1,401.0) (1,148.0) (651.0)

Other Compr. Income Components Recognized on the BS

Net Actuarial Loss/Gain 523.0 502.0 293.0 202.0 76.0 (58.0)
Prior Service Cost/Benefit (1,415.0) (1,392.0) (1,190.0) (994.0) (830.0) (688.0)
Net Amount Recognized (892.0) (889.0) (897.0) (792.0) (754.0) (746.0)

Consolidated Balance Sheet Amounts

Current Liabilities (31.0) (30.0) (31.0) (29.0) (24.0) (6.0)
Long Term Liabilities (1,809.0) (1,766.0) (1,504.0) (1,371.0) (1,124.0) (645.0)

Net Periodic Benefit Cost to be Recognized in the Subsequent Period

Prior Service Cost/Benefit (164.0) (184.0) (181.0) (178.0) (172.0) -
Net Actuarial Loss/Gain 29.0 31.0 9.0 4.0 (1.0) -
Total Amount to be Recognized (135.0) (153.0) (172.0) (175.0) (172.0) -

Other Post-Retirement Benefit Related Items

Health Care Cost Trend Rate, Ultimate - - - - 4.5% 4.5%
Benefit Info Date Dec-31-2015 Dec-31-2016 Dec-31-2017 Dec-31-2018 Dec-31-2019 Dec-31-2020

Pension Information - Domestic

Defined Benefit Net Periodic Cost
Def. Benefit Service Cost 309.0 275.0 293.0 - - -
Def. Benefit Interest Cost 730.0 699.0 688.0 653.0 676.0 533.0
Def. Benefit Return On Assets (1,089.0) (958.0) (1,005.0) (1,040.0) (890.0) (1,015.0)
Def. Benefit Other Cost 976.0 565.0 573.0 302.0 432.0 420.0
Def. Benefit Total Cost 926.0 581.0 548.0 (86.0) 216.0 (62.0)

Defined Benefit Obligation

Beg. Def. Benefit Obligation 18,056.0 16,269.0 16,997.0 18,197.0 16,421.0 17,886.0
Def. Benefit Service Cost 309.0 275.0 293.0 - - -
Def. Benefit Interest Cost 730.0 699.0 688.0 653.0 676.0 533.0
Def. Benefits Paid (477.0) (640.0) (575.0) (604.0) (618.0) (445.0)
Def. Benefit Settlement/Curtailment (2,124.0) (517.0) (929.0) (451.0) (762.0) (767.0)
Other Adj. To Def. Benefit Obligation (227.0) 910.0 1,724.0 (1,377.0) 2,169.0 1,099.0
Proj. Benefit Obligation (Pension) - Domestic 16,269.0 16,997.0 18,197.0 16,421.0 17,886.0 18,306.0
Accum. Benefit Obligation 16,100.0 16,800.0 18,200.0 16,421.0 17,886.0 18,306.0

Plan Assets
Beg. Plan Assets 12,706.0 11,633.0 12,556.0 14,284.0 13,051.0 14,586.0
Actual Return on Plan Assets (124.0) 939.0 2,005.0 (796.0) 2,760.0 1,974.0
Employer Contributions 1,158.0 1,151.0 1,238.0 629.0 155.0 1,432.0
Benefits Paid (477.0) (640.0) (575.0) (604.0) (618.0) (445.0)
Plan Settlement/Curtailment (2,127.0) (527.0) (940.0) (463.0) (762.0) (767.0)
Other Plan Adjustments 496.0 - - - - (687.0)
Total Plan Assets 11,633.0 12,556.0 14,284.0 13,051.0 14,586.0 16,094.0

Weighted Avg. Assumptions on Net Periodic Cost

Net Periodic Cost Disc. Rate - Min 4.2% 4.5% 4.3% 3.8% 4.4% 3.3%
Net Periodic Cost Disc. Rate - Max 4.2% 4.5% 4.3% 3.8% 4.4% 3.3%
Rate of Comp. Increase - Min 2.8% 2.8% 2.8% 2.8% - -
Rate of Comp. Increase - Max 2.8% 2.8% 2.8% 2.8% - -
Exp. Long-Term Rate of Return on Assets - Min 8.3% 8.0% 8.0% 7.5% 7.2% 7.0%
Exp. Long-Term Rate of Return on Assets - Max 8.3% 8.0% 8.0% 7.5% 7.2% 7.0%

Breakdown of Plan Assets

Plan Assets - Equities (%) 40.2% 40.1% 37.5% 31.3% 31.8% 28.4%
Plan Assets - Fixed Income (%) 38.6% 40.2% 44.2% 50.5% 51.2% 55.1%
Other Plan Assets (%) 21.2% 19.7% 18.3% 18.2% 17.0% 16.6%

Breakdown of Plan Assets

Plan Assets - Equities 4,676.5 5,035.0 5,356.5 4,085.0 4,638.3 4,570.7
Plan Assets - Fixed Income 4,490.3 5,047.5 6,313.5 6,590.8 7,468.0 8,867.8
Other Plan Assets 2,466.2 2,473.5 2,614.0 2,375.3 2,479.6 2,671.6

Weighted Avg. Assumptions on Def. Benefit Obligation

PBO Assumed Rate of Return - Min 4.5% 4.3% 3.8% 4.4% 3.3% 2.6%
PBO Assumed Rate of Return - Max 4.5% 4.3% 3.8% 4.4% 3.3% 2.6%
Rate of PBO Compensation Increase - Min 2.8% 2.8% 2.8% - - -
Rate of PBO Compensation Increase - Max 2.8% 2.8% 2.8% - - -

Estimated Future Benefits Paid

Est. Future Benefits Paid - 1st Yr 1,126.0 1,671.0 1,385.0 1,554.0 1,666.0 1,266.0
Est. Future Benefits Paid - 2nd Yr 1,776.0 1,186.0 1,200.0 1,210.0 1,202.0 1,157.0
Est. Future Benefits Paid - 3rd Yr 1,110.0 1,065.0 1,215.0 1,172.0 1,163.0 1,148.0
Est. Future Benefits Paid - 4th Yr 1,057.0 1,071.0 1,181.0 1,133.0 1,156.0 1,136.0
Est. Future Benefits Paid - 5th Yr 1,073.0 1,042.0 1,155.0 1,121.0 1,131.0 1,086.0
Est. Future Benefits Paid - Thereafter 5,029.0 4,894.0 5,378.0 5,282.0 5,194.0 5,049.0

Balance Sheet Reconciliation Items

Accrued Benefit Liability (126.0) (312.0) (160.0) (168.0) (189.0) (127.0)

Adj. for Liability Recognized on Balance Sheet

Net Asset/Liability Recognized on Balance Sheet (4,635.0) (4,440.0) (3,913.0) (3,369.0) (3,300.0) (2,211.0)

Other Compr. Income Components Recognized on the BS

Net Actuarial Loss/Gain 4,691.0 5,068.0 5,238.0 5,431.0 5,296.0 5,641.0
Prior Service Cost/Benefit 29.0 25.0 22.0 (2.0) 2.0 4.0
Net Amount Recognized 4,720.0 5,094.0 5,258.0 5,430.0 5,299.0 5,645.0

Consolidated Balance Sheet Amounts

Current Liabilities (126.0) (312.0) (160.0) (168.0) (189.0) (127.0)
Long Term Liabilities (4,508.0) (4,127.0) (3,754.0) (3,201.0) (3,111.0) (2,084.0)

Net Periodic Benefit Cost to be Recognized in the Subsequent Period

Prior Service Cost/Credit 4.0 4.0 1.0 (4.0) (4.0) -
Net Actuarial Loss/Gain 435.0 464.0 137.0 157.0 141.0 -
Total Amount to be Recognized 439.0 468.0 138.0 154.0 138.0 -

Other Pension Related Items

Est. Contributions - Next Year 1,126.0 1,312.0 660.0 178.0 1,465.0 127.0
Benefit Info Date Dec-31-2015 Dec-31-2016 Dec-31-2017 Dec-31-2018 Dec-31-2019 Dec-31-2020

OPEB Information - Domestic

Defined Benefit Net Periodic Cost
Def. Benefit Service Cost 55.0 41.0 42.0 39.0 37.0 38.0
Def. Benefit Interest Cost 117.0 101.0 90.0 72.0 75.0 49.0
Def. Benefit Expected Return on Assets (53.0) (34.0) (36.0) (37.0) (33.0) (36.0)
Def. Benefit Other Cost (139.0) (168.0) (170.0) (186.0) (225.0) (170.0)
Def. Benefit Total Cost (21.0) (59.0) (75.0) (111.0) (146.0) (118.0)

Defined Benefit Obligation

Beg. Def. Benefit Obligation 3,168.0 2,463.0 2,254.0 2,028.0 1,870.0 1,667.0
Def. Benefit Service Cost 55.0 41.0 42.0 39.0 37.0 38.0
Def. Benefit Interest Cost 117.0 101.0 90.0 72.0 75.0 49.0
Def. Benefit Employee Contributions 79.0 85.0 94.0 102.0 84.0 88.0
Def. Benefits Paid (300.0) (282.0) (280.0) (249.0) (221.0) (201.0)
Foreign Exchange Adj. (20.0) - 5.0 (4.0) (1.0) 2.0
Def. Benefit Settlement/Curtailment (3.0) - 1.0 (1.0) - -
Other Adj. To Def. Benefit Obligation (633.0) (155.0) (176.0) (118.0) (177.0) (406.0)
Proj. Benefit Obligation 2,463.0 2,254.0 2,028.0 1,870.0 1,667.0 1,238.0

Accum. Benefit Obligation 2,463.0 2,254.0 2,028.0 1,870.0 1,667.0 1,238.0

Plan Assets
Beg. Plan Assets 762.0 622.0 458.0 494.0 469.0 519.0
Actual Return on Plan Assets (3.0) 44.0 39.0 (22.0) 50.0 69.0
Employer Contributions 84.0 - 183.0 145.0 137.0 113.0
Participant Contributions 79.0 85.0 94.0 102.0 84.0 88.0
Benefits Paid (300.0) (282.0) (280.0) (249.0) (221.0) (201.0)
Other Plan Adjustments - (12.0) - - - -
Total Plan Assets 622.0 458.0 494.0 469.0 519.0 588.0

Weighted Avg. Assumptions on Net Periodic Cost

Net Periodic Cost Disc. Rate - Min 4.2% 4.5% 4.2% 3.7% 4.3% 3.2%
Net Periodic Cost Disc. Rate - Max 4.2% 4.5% 4.2% 3.7% 4.3% 3.2%
Exp. Long-Term Rate of Return on Assets - Min 8.3% 8.0% 8.0% 7.5% 7.3% 7.0%
Exp. Long-Term Rate of Return on Assets - Max 8.3% 8.0% 8.0% 7.5% 7.3% 7.0%

Breakdown of Plan Assets

Plan Assets - Equities (%) 12.8% - - - - -
Plan Assets - Fixed Income (%) 12.2% - - - - -
Other Plan Assets (%) 75.0% 100.0% 100.0% 100.0% 100.0% 100.0%

Breakdown of Plan Assets

Plan Assets - Equities 79.6 - - - - -
Plan Assets - Fixed Income 75.9 - - - - -
Other Plan Assets 466.5 458.0 494.0 469.0 519.0 588.0

Weighted Avg. Assumptions on Def. Benefit Obligation

PBO Assumed Rate of Return - Min 4.5% 4.2% 3.7% 4.3% 3.2% 2.5%
PBO Assumed Rate of Return - Max 4.5% 4.2% 3.7% 4.3% 3.2% 2.5%
Estimated Future Benefits Paid
Est. Future Benefits Paid - 1st Yr 198.0 186.0 173.0 166.0 153.0 97.0
Est. Future Benefits Paid - 2nd Yr 205.0 196.0 179.0 171.0 137.0 94.0
Est. Future Benefits Paid - 3rd Yr 208.0 198.0 181.0 171.0 137.0 92.0
Est. Future Benefits Paid - 4th Yr 208.0 197.0 179.0 168.0 136.0 89.0
Est. Future Benefits Paid - 5th Yr 207.0 196.0 173.0 165.0 134.0 86.0
Est. Future Benefits Paid - Thereafter 1,001.0 919.0 802.0 777.0 642.0 430.0

Balance Sheet Reconciliation Items

Accrued Benefit Liability (31.0) (30.0) (31.0) (29.0) (24.0) (6.0)

Adj. for Liability Recognized on Balance Sheet

Net Asset/Liability Recognized on Balance Sheet (1,841.0) (1,796.0) (1,534.0) (1,401.0) (1,148.0) (651.0)

Other Compr. Income Components Recognized on the BS

Net Actuarial Loss/Gain 523.0 502.0 293.0 202.0 76.0 (58.0)
Prior Service Cost/Benefit (1,415.0) (1,392.0) (1,190.0) (994.0) (830.0) (688.0)
Net Amount Recognized (892.0) (889.0) (897.0) (792.0) (754.0) (746.0)

Consolidated Balance Sheet Amounts

Current Liabilities (31.0) (30.0) (31.0) (29.0) (24.0) (6.0)
Long Term Liabilities (1,809.0) (1,766.0) (1,504.0) (1,371.0) (1,124.0) (645.0)

Net Periodic Benefit Cost to be Recognized in the Subsequent Period

Prior Service Cost/Credit (164.0) (184.0) (181.0) (178.0) (172.0) -
Net Actuarial Loss/Gain 29.0 31.0 9.0 4.0 (1.0) -
Total Amount to be Recognized (135.0) (153.0) (172.0) (175.0) (172.0) -

Other Post-Retirement Benefit Related Items

Health Care Cost Trend Rate, Ultimate - - - - 4.5% 4.5%
Benefit Info Date Dec-31-2015 Dec-31-2016 Dec-31-2017 Dec-31-2018 Dec-31-2019 Dec-31-2020

Pension Information - Foreign

Defined Benefit Net Periodic Cost
Def. Benefit Service Cost 186.0 165.0 171.0 136.0 125.0 146.0
Def. Benefit Interest Cost 307.0 233.0 204.0 212.0 215.0 164.0
Def. Benefit Return on Assets (418.0) (381.0) (345.0) (360.0) (317.0) (306.0)
Def. Benefit Other Cost 202.0 98.0 117.0 97.0 91.0 128.0
Def. Benefit Total Cost 277.0 115.0 147.0 84.0 115.0 132.0
Defined Benefit Obligation
Beg. Def. Benefit Obligation 10,796.0 9,214.0 9,691.0 10,607.0 9,952.0 11,059.0
Def. Benefit Service Cost 186.0 165.0 171.0 136.0 125.0 146.0
Def. Benefit Interest Cost 307.0 233.0 204.0 212.0 215.0 164.0
Def. Benefit Employee Contributions 7.0 7.0 6.0 7.0 7.0 8.0
Def. Benefits Paid (389.0) (358.0) (357.0) (373.0) (360.0) (372.0)
Foreign Exchange Adj. (938.0) (781.0) 760.0 (457.0) (33.0) 646.0
Def. Benefit Settlement/Curtailment (501.0) (59.0) (31.0) (37.0) (36.0) (34.0)
Other Adj. To Def. Benefit Obligation (254.0) 1,269.0 164.0 (142.0) 1,187.0 384.0
Proj. Benefit Obligation (Pension) - Foreign 9,214.0 9,691.0 10,607.0 9,952.0 11,059.0 12,001.0

Accum. Benefit Obligation 8,800.0 9,300.0 10,100.0 9,500.0 10,600.0 11,500.0

Plan Assets
Beg. Plan Assets 8,588.0 7,959.0 7,683.0 8,863.0 8,215.0 8,956.0
Actual Return on Plan Assets 290.0 693.0 811.0 (77.0) 873.0 868.0
Employer Contributions 558.0 209.0 160.0 209.0 230.0 197.0
Participant Contributions 7.0 7.0 6.0 7.0 7.0 8.0
Benefits Paid (389.0) (358.0) (357.0) (373.0) (360.0) (372.0)
Foreign Exchange Adjustments (602.0) (782.0) 561.0 (380.0) 42.0 462.0
Plan Settlement/Curtailment (499.0) (45.0) (31.0) (34.0) (34.0) (34.0)
Other Plan Adjustments 6.0 (1.0) 30.0 - (16.0) (276.0)
Total Plan Assets 7,959.0 7,683.0 8,863.0 8,215.0 8,956.0 9,811.0

Weighted Avg. Assumptions on Net Periodic Cost

Net Periodic Cost Disc. Rate - Min 3.0% 2.7% 2.1% 2.0% 2.2% 1.5%
Net Periodic Cost Disc. Rate - Max 3.0% 2.7% 2.1% 2.0% 2.2% 1.5%
Rate of Comp. Increase - Min 2.7% 2.6% 2.6% 2.5% 1.4% 2.9%
Rate of Comp. Increase - Max 2.7% 2.6% 2.6% 2.5% 1.4% 2.9%
Exp. Long-Term Rate of Return on Assets - Min 5.5% 5.2% 4.7% 4.4% 3.9% 3.6%
Exp. Long-Term Rate of Return on Assets - Max 5.5% 5.2% 4.7% 4.4% 3.9% 3.6%

Breakdown of Plan Assets

Plan Assets - Equities (%) 39.2% 34.7% 34.4% 22.9% 21.5% 20.9%
Plan Assets - Fixed Income (%) 41.4% 45.9% 43.6% 49.3% 49.4% 52.6%
Other Plan Assets (%) 19.4% 19.4% 21.9% 27.9% 29.2% 26.6%

Breakdown of Plan Assets

Plan Assets - Equities 3,119.9 2,666.0 3,048.9 1,881.2 1,925.5 2,050.5
Plan Assets - Fixed Income 3,295.0 3,526.5 3,864.3 4,050.0 4,424.3 5,160.6
Other Plan Assets 1,544.0 1,490.5 1,941.0 2,292.0 2,615.2 2,609.7

Weighted Avg. Assumptions on Def. Benefit Obligation

PBO Assumed Rate of Return - Min 3.1% 2.4% 2.3% 2.5% 1.7% 1.5%
PBO Assumed Rate of Return - Max 3.1% 2.4% 2.3% 2.5% 1.7% 1.5%
Rate of PBO Compensation Increase - Min 2.6% 2.6% 2.5% 1.4% 1.4% 2.9%
Rate of PBO Compensation Increase - Max 2.6% 2.6% 2.5% 1.4% 1.4% 2.9%

Estimated Future Benefits Paid

Est. Future Benefits Paid - 1st Yr 350.0 331.0 368.0 354.0 355.0 371.0
Est. Future Benefits Paid - 2nd Yr 348.0 333.0 373.0 372.0 358.0 375.0
Est. Future Benefits Paid - 3rd Yr 352.0 335.0 385.0 380.0 364.0 375.0
Est. Future Benefits Paid - 4th Yr 359.0 350.0 394.0 385.0 366.0 385.0
Est. Future Benefits Paid - 5th Yr 370.0 356.0 401.0 387.0 375.0 393.0
Est. Future Benefits Paid - Thereafter 1,959.0 1,867.0 2,101.0 2,068.0 1,992.0 2,086.0

Balance Sheet Reconciliation Items

Accrued Benefit Liability (25.0) (28.0) (26.0) (28.0) (30.0) (31.0)

Adj. for Liability Recognized on Balance Sheet

Net Asset/Liability Recognized on Balance Sheet (1,255.0) (2,008.0) (1,745.0) (1,738.0) (2,103.0) (2,191.0)

Other Compr. Income Components Recognized on the BS

Net Actuarial Loss/Gain 1,979.0 2,629.0 2,322.0 2,372.0 2,921.0 3,056.0
Prior Service Cost/Benefit (29.0) (40.0) (34.0) - 21.0 31.0
Net Amount Recognized 1,949.0 2,589.0 2,288.0 2,372.0 2,942.0 3,087.0

Consolidated Balance Sheet Amounts

Long Term Assets 572.0 300.0 454.0 401.0 453.0 522.0
Current Liabilities (25.0) (28.0) (26.0) (28.0) (30.0) (31.0)
Long Term Liabilities (1,801.0) (2,279.0) (2,172.0) (2,111.0) (2,526.0) (2,681.0)

Net Periodic Benefit Cost to be Recognized in the Subsequent Period

Prior Service Cost/Benefit (2.0) (4.0) (4.0) (3.0) (3.0) -
Net Actuarial Loss/Gain 91.0 113.0 101.0 81.0 124.0 -
Total Amount to be Recognized 89.0 109.0 97.0 78.0 121.0 -
Other Pension Related Items
Est. Contributions - Next Year 170.0 175.0 226.0 177.0 172.0 282.0
Benefit Info Date Dec-31-2015 Dec-31-2016 Dec-31-2017 Dec-31-2018 Dec-31-2019 Dec-31-2020
Pfizer Inc. (NYSE:PFE) > Financials > Segments

In Millions of the reported currency. View By: Line Items Restatement: Latest Filings
Period Type: Annual Order: Latest on Right
Currency: Reported Currency Conversion: Today's Spot Rate
Units: S&P Capital IQ (Defaul Decimals: Capital IQ (Default)

Business Segments
For the Fiscal Period Ending
12 months Reclassified Reclassified Reclassified Reclassified 12 months
Currency USD USD USD USD USD USD
Revenues
Biopharma - - 35,530.0 40,825.0 41,172.0 41,908.0
Upjohn - - 13,447.0 - - -
Other - - 3,472.0 - - -
Corporate and Other Unallocated - - 97.0 - - -
Innovative Health (IH) 26,758.0 29,197.0 - - - -
Essential Health (EH) 22,094.0 23,627.0 - - - -
Total Revenues 48,852.0 52,824.0 52,546.0 40,825.0 41,172.0 41,908.0

Interest Expense
Biopharma - - - (1,316.0) (1,573.0) (1,449.0)
Total Interest Expense - - - (1,316.0) (1,573.0) (1,449.0)

Net Profit Before Tax

Biopharma - - 22,194.0 3,594.0 11,485.0 7,497.0
Upjohn - - 9,348.0 - - -
Other (2,914.0) (3,020.0) (5,302.0) - - -
Corporate and Other Unallocated - - (6,299.0) - - -
Unallocated Purchase Accounting Adjustments (3,953.0) (4,185.0) (4,758.0) - - -
Unallocated Acquisition-Related Costs (894.0) (785.0) (456.0) - - -
Unallocated Certain Significant Items (4,321.0) (5,888.0) (2,423.0) - - -
Innovative Health (IH) 14,581.0 16,166.0 - - - -
Essential Health (EH) 12,714.0 13,065.0 - - - -
Corporate (5,607.0) (5,448.0) - - - -
Other Unallocated (642.0) (1,554.0) - - - -
Total Net Profit Before Tax 8,964.0 8,351.0 12,304.0 3,594.0 11,485.0 7,497.0
Tax Expense
Biopharma - - - (266.0) 618.0 477.0
Total Tax Expense - - - (266.0) 618.0 477.0

Net Profit After Tax

Biopharma - - - 11,153.0 16,273.0 9,616.0
Total Net Profit After Tax - - - 11,153.0 16,273.0 9,616.0

Assets
Biopharma - - - - 167,594.0 154,229.0
Total Assets - - - - 167,594.0 154,229.0

Depreciation & Amortization

Biopharma - - 881.0 6,112.0 5,755.0 4,758.0
Upjohn - - 125.0 - - -
Other 76.0 85.0 142.0 - - -
Corporate and Other Unallocated - - 465.0 - - -
Unallocated Purchase Accounting Adjustments 3,573.0 3,890.0 4,565.0 - - -
Unallocated Acquisition-Related Costs 75.0 7.0 39.0 - - -
Unallocated Certain Significant Items 48.0 200.0 52.0 - - -
Innovative Health (IH) 552.0 583.0 - - - -
Essential Health (EH) 446.0 600.0 - - - -
Corporate 355.0 356.0 - - - -
Other Unallocated 33.0 35.0 - - - -
Total Depreciation & Amortization 5,158.0 5,756.0 6,269.0 6,112.0 5,755.0 4,758.0

Capital Expenditure
Biopharma - - - (2,136.0) (2,490.0) (2,791.0)
Total Capital Expenditure - - - (2,136.0) (2,490.0) (2,791.0)

Filing Date Feb-22-2018 Feb-28-2019 Feb-27-2020 Feb-25-2021 Feb-25-2021 Feb-25-2021

Geographic Segments
For the Fiscal Period Ending
12 months Reclassified Reclassified Reclassified Reclassified 12 months
Currency USD USD USD USD USD USD
Revenues
United States (U.S.) 21,704.0 26,369.0 26,026.0 20,119.0 20,593.0 21,712.0
Developed Europe 9,714.0 9,306.0 8,508.0 7,997.0 7,729.0 7,788.0
Developed Rest of World 6,298.0 6,729.0 6,612.0 4,090.0 4,022.0 4,036.0
Emerging Markets 11,136.0 10,420.0 11,399.0 8,618.0 8,828.0 8,372.0
Total Revenues 48,852.0 52,824.0 52,545.0 40,824.0 41,172.0 41,908.0

Assets
United States (U.S.) 7,072.0 6,649.0 6,971.0 7,089.0 7,194.0 7,821.0
Developed Europe 4,376.0 4,228.0 4,345.0 4,204.0 4,238.0 4,775.0
Developed Rest of World 660.0 643.0 632.0 490.0 453.0 413.0
Emerging Markets 1,658.0 1,797.0 1,917.0 1,602.0 1,083.0 890.0
Total Assets 13,766.0 13,317.0 13,865.0 13,385.0 12,968.0 13,899.0

Filing Date Feb-22-2018 Feb-28-2019 Feb-27-2020 Feb-25-2021 Feb-25-2021 Feb-25-2021